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Abstract	
	
	
Introduction		
Mastocytosis,	one	of	the	subcategories	of	myeloproliferative	neoplasms,	results	
from	a	colonel,	neoplastic	proliferation	of	morphologically	and	
immunophenotypically	abnormal	mast	cells	which	accumulate	primarily	in	the	skin	
and	bone	marrow.	Prevalence	is	reported	to	be	13	in	100,000	of	the	population,	
with	an	equal	male	to	female	preponderance.	The	clinical	spectrum	is	
heterogeneous	and	ranges	from	relatively	benign	cutaneous	mastocytosis	(CM),	
with	isolated	skin	lesions,	to	a	more	aggressive	variant,	systemic	mastocytosis	(SM).		
	
Aim	
To	carry	out	both	a	global	discovery	and	a	targeted	analysis	of	the	proteome	of	
plasma	from	peripheral	blood	of	systemic	mastocytosis	patients	and	compare	to	
healthy	controls,	to	understand	the	molecular	mechanism	of	systemic	mastocytosis	
and	to	identify	novel	disease	biomarkers.		
	
Methods	
Peripheral	blood	was	collected	by	venepuncture	at	the	antecubital	fossa	from	
systemic	mastocytosis	patients	(n=13)	and	healthy	controls	(n=7).	Following	
immune-depletion	of	high	abundance	proteins	and	tryptic	digestion,	plasma	
samples	were	loaded	onto	a	SciEx	6600	Triple	TOF	mass-spectrometer.		
	
Results	
SWATH-MS	identified	1437	proteins,	off	which	360	were	upregulated.	Further	
analysis	identified	these	as	being	involved	in	immune	system	regulation	and	
leukocyte	activation.	ELISA	was	used	to	measure	the	levels	of	proteins	common	to	
all	pathways	involved	in	immune	regulation	and	inflammation.	The	results	of	ELISA	
demonstrated	significantly	increased	circulating	plasma	levels	of	CRP,	CXCL7,	LBP,	
TGFb1	and	PDGFrb	in	systemic	mastocytosis	compared	to	controls.	Circulating	
plasma	levels	of	B2M	were	also	increased	in	patients,	although	this	did	not	reach	
the	level	of	statistical	significance.		
	
	
Conclusion	
The	results	of	the	current	investigation	demonstrate,	the	up-regulated	proteins	
identified	are	involved	in	immune	system	regulation	and	inflammation,	suggesting	
a	central	role	of	the	inflammatory	response	in	the	patho-physiology	of	systemic	
mastocytosis.		
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1.1	Introduction	
According	to	the	World	Health	Organisation	(WHO),	mastocytosis	is	considered	one	
of	the	eight	subcategories	of	myeloproliferative	neoplasms.	Mastocytosis	results	
from	a	clonal,	neoplastic	proliferation	of,	morphologically	and	
immunophenotypically,	abnormal	mast	cells	which	accumulate	primarily	in	the	skin	
and	bone	marrow	(Pardanani,	2016).	
Mastocytosis	has	a	reported	prevalence	of	13	in	100,000	of	the	population,	with	an	
equal	male	to	female	preponderance,	however	underdiagnoses	is	assumed	due	to	
clinical	misclassification	and	non-specific	symptomology	(Brockow,	2014).	
The	clinical	spectrum	of	mastocytosis	is	heterogeneous	and	ranges	from	relatively	
benign	cutaneous	mastocytosis	(CM),	with	isolated	skin	lesions,	particularly	in	
paediatric	patients	who	generally	experience	spontaneous	regression	at	puberty	
and	is	associated	with	an	excellent	prognosis	(Magliacane	et	al.,	2014),	to	a	more	
aggressive	variant,	systemic	mastocytosis	(SM).	Systemic	mastocytosis	generally	
occurs	in	adults	and	is	associated	with	widespread	systemic	involvement	associated	
with	multiorgan	dysfunction	and	reduced	survival	(Pardanani,	2016).		
	
Mastocytosis	patients	present	with	a	broad	spectrum	of	widely	varying	clinical	
signs	and	symptoms	which,	apart	from	the	characteristic	skin	lesions	of	urticaria	
pigmoentosa,	lack	specificity	to	point	clearly	to	a	definitive	diagnosis	(Horney	et	al.,	
2008).	Nevertheless	clinical	diagnosis	of	mastocytosis	is	determined	according	to	
the	2016	WHO	criteria,	which	includes	the	identification	of	neoplastic	mast	cells	
using	morphological,	immunophenotypic	and/or	molecular	criteria	(Pardanani,	
2016).		
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The	clinical	signs	and	symptoms	of	mastocytosis	include	fatigue,	pruritus,	flushing,	
tachycardia,	abdominal	pain,	bone	pain	and	rarely	neuro-psychiatric	symptoms.	
The	clinical	signs	and	symptoms	are	mediated	by	mast	cell	activation	and	release	of	
inflammatory	and	immunological	mediators,	consequently	clinical	severity	can,	in	
part,	be	related	to	the	degree	of	mast	cell	infiltration	and	activation	(Metcalfe	et	
al.,	2017).	Clinical	management	of	mastocytosis,	regardless	of	subtype,	involves	the	
control	of	immediate,	possibly	severe	symptoms,	by	the	use	of,	for	example,	H1-	
antihistamines	for	the	reduction	of	pruritus	and	flushing,	and	corticosteroids	for	
bone	pain	(Komi	et	al.,	2017).		
1.2	The	Mast	Cell		
In	1878,	Paul	Ehrlich	was	the	first	to	describe	mast	cells	or	“mastzellen”	in	
connective	tissue	that	stained	reddish	purple	with	aniline	dyes	(Metcalfe,	2008).	
Ehrlich	also	went	onto	describe	the	pivotal	role	of	mast	cells	in	inflammation.		
Several	developments,	such	as	the	discovery	of	histamine,	mast	cell	growth	factors	
and	the	role	of	mast	cells	in	inflammatory	diseases,	has	since	occurred	
(Krishnaswamy	et	al.,	2001).	(Figure	1)			
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Figure	1:	Photomicrograph	of	Human	mast	cells	(x400	magnification).	Human	mast	cells	cultured	
from	peripheral	blood	in	stem	cell	factor,	stained	with	toluidine	blue	(Metcalfe,	2008).	
	
Mast	cells	are	found	in	peripheral	tissue,	such	as	connective	tissue	and	the	dermal	
layer	of	the	skin,	where	they	play	a	central	role	in	mediating	inflammation	and	
immediate	allergic	reactions	(Payne	and	Kam,	2004).	Mast	cells	are	heavily	
granulated,	wandering	cells	which	maybe	recruited	into	peripheral	tissues,	such	as	
lungs,	mucosa,	dermis	of	skin	and	submucosa	of	the	intestines	where	they	
differentiate	and	mature	under	the	influence	of	mast	cell	growth	factors	
(Krishnaswamy	et	al.,	2001).	
	
Mast	cells	are	derived	from	haematopoietic	progenitor	cells	from	bone	marrow.	
Circulating	pluripotent	progenitor	(CD34+/CD117+)	cells,	migrate	into	the	peripheral	
tissue	and	mature	under	the	influence	of	stem	cell	factor	(SCF)	into	
(FceR1+/CD117+)	mast	cells.	Stem	cell	factor,	which	is	produced	by	a	number	of	
cells,	notably	fibroblasts	and	endothelial	cells,	is	a	ligand	for	the	c-KIT	(CD117)	
receptor	expressed	by	mature	mast	cells,	leading	to	activation	of	c-KIT	to	mediate	
the	intracellular	signalling	pathways	(Figure	2).	
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Figure	2:	Mast	cell	development:	Mast	cells	develop	from	CD34+	/CD117+	progenitors	that	originate	
from	the	bone	marrow.	Once	the	bone	marrow	progenitors	are	released	from	the	bone	marrow,	
they	enter	circulation	where	they	follow	a	controlled	trafficking	pattern	with	the	help	of	
interactions	between	integrin’s	and	their	receptors.	Upon	reaching	their	target	tissues,	they	mature	
into	mast	cells	under	the	influence	of	growth	factors	(Komi	et	al,.	2017).		
	
Mast	cells	are	specialised	secretory	cells	of	the	innate	immune	system.	They	play	
an	important	role	in	host	defence	by	producing	and	releasing	proinflammatory	
mediators,	chemotactic	factors	and	immunoregulatory	cytokines	(Komi	et	al.,	2017)	
(Table	1).	Within	their	cytoplasm,	mast	cells	contain	dense	metachromatic	granules	
containing	heparin,	histamine	and	a	variety	of	proteases.	Upon	stimulation	of	the	
	 17	
cell	surface	Fc	receptors	with	their	physiological	ligand	IgE,	the	mast	cells	
immediately	release	the	contents	of	the	secretory	granules	in	the	process	of	
degranulation.	In	addition,	degranulation	may	be	induced	by	a	number	of	physical	
factors,	including	toxins	and	venoms	(Payne	and	Kam,	2004).	
	
Table	1:	Mast	cell	proinflammatory	mediators,	chemotactic	factors	and	immunoregulatory	
cytokines	release.	Major	human	mast	cell	derived	mediators	released	upon	degranulation	and	their	
physiological	effects	upon	the	body	(Adapted	from	Metcalfe,	2008).		
	
Class	 Mediators	 Physiological	effects		
Preformed	
mediators	
Histamine,	Serotonin,	Heparin,	
Neutral	Proteases	(tryptase	and	
chymase),	Carboxypeptidase,	
Cathepsin	G,	Major	basic	protein,	
Acid	Hydrolases,	Peroxidase,	
Phospholipases	
Vasodilation,	Vasoconstriction,	
Angiogenesis,	Mitogenisis,	Pain,	Protein	
processing/degradation,	lipid/proteoglycan	
hydrolysis,	Arachidonic	acid	generation,	
Tissue	damaged	and	repair,	Inflammation	
Lipid	
mediators		
LTB4,	LTC4,	PGE2,	PGD2,	PAF	 Leukocyte	chemotaxis,	Vasoconstriction,	
Bronchoconstriction,	Platelet	activation,	
Vasodilation	
	
Cytokines		 TNF-a,	TGF-b,	IFN-a,	IFN-,	b	IL-1a,	
IL-1	b,	IL-5,	IL-6,	IL-13,	IL-16,	IL-18	
Inflammation,	leukocyte,	
migration/proliferation	
	
Chemokines	 IL-8,	I-309,	MCP-1,	MIP-1aS,	MIP1	
b,	MCP-3,	RANTES,	EOTAXIN,	
MCAF		
Chemoattraction	and	tissue	infiltration	of	
leukocytes		
	
Growth	
Factors		
SCF,	M-CSF,	GM-CSF,	BFGF,	VEGF,	
NGF,	PDGF	
Growth	of	various	cell	types,	Vasodilation,	
Neovascularization,	Angiogenesis.		
	
	
	
The	mast	cell	receptor	c-KIT	(CD117),	is	a	type	III	tyrosine	kinase	(Komi	et	al.,	2017),	
consisting	of	five	extracellular	immunoglobulin	like	domains	and	a	single	
transmembrane	spanning	region	(Figure	3).	Three	of	the	Ig	domains	possess	
complementary	shape	and	charge	and	are	the	ligand	binding	site	for	SCF,	while	
domains	four	and	five	permit	receptor	dimerization	(Metcalfe,	2008).	The	
intracellular	juxtamembrane	region,	located	between	the	plasma	membrane	and	
the	kinase	domain,	controls	the	c-KIT	kinase	activity.	In	addition,	the	kinase	domain	
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is	composed	of	2	sub-domains	designated,	tyrosine	kinase	domain	1	and	2.	Stem	
cell	factor	mediated	c-KIT	signalling	plays	important	roles	in	mediating	
angiogenesis,	migration,	cell	survival	and	proliferation	of	mast	cells	(Komi	et	al.,	
2017).	Binding	of	KIT	leads	to	homodimerization	of	c-KIT	due	to	the	interactions	of	
Ig-like	domain	4/5	of	two	monomeric	KIT	receptors.	These	interactions	lead	to	the	
consecutive	transphophylation	in	the	regions	juxtamembrane,	kinase	insert,	kinase	
domain	and	COOH	terminal.	The	phosphorylated	residues	act	like	docking	sites	for	
signalling	molecules	Src	and	Shc	kinase,	PI3K	and	PLCy.	Sos,	PI3K,	PLCy	and	JAK2	
active	MAPK	cascade,	and	as	a	result	causes	Ca2	influx	and	activation	of	
transcription	factors	required	for	mast	cell	activation.	This	SCF	induced	activation	
of	the	JAK2	results	in	STAT5	and	STAT6	activation	which	intern	promotes	mast	cell	
development,	survival	and	proliferation	(Figure	4).		
	
Cross	linking	of	IgE	bound	allergen	triggers	the	FcER1	signalling	pathway	via	the	
recruitment	of	the	Syk,	tyrosine	kinase,	to	the	y-chain-	ITAMs	following	
translocation	to	the	phosphorylation	of	specific	tyrosine	within	these	motifs	by	Lyn,	
resulting	in	activation	of	Syk,	phosphorylation	of	the	transmembrane	adaptor	
module	LAT,	which	in	turn	coordinates	downstream	signalling	pathways.	This	
results	in	the	activation	of	PLCy1/2,	which	are	essential	signals	for	mast	cell	
mediator	release.		
A	parallel	pathway	is	also	initiated	by	tyrosine	kinase,	Fyn,	which	leads	to	the	
activation	of	PI3K,	which	are	also	required	for	optimal	degranulation	and	cytokine	
production	(Figure	5).		
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GTP	exchangers	Sos	and	Vav	activate	the	Ras-Raf-Mapk	pathway,	which	
contributes	to	the	activation	of	specific	transcription	factors	required	for	cytokine	
production	(Figure	5),	(Metcalfe,	2008	and	Komi,	2017).	
	
	
	
Figure	3:	Mast	cell	receptor	c-KIT	(CD117).	The	c-KIT	receptor	is	a	type	III	tyrosine	kinase	consisting	
of	five	extracellular	immunoglobulin	like	domains	and	a	single	transmembrane	spanning	region.	
Three	of	the	Ig	domains	possess	complementary	shape	and	charge	and	are	the	ligand	binding	site	
for	SCF,	while	domains	four	and	five	permit	receptor	dimerization	(Figure	adapted	from	Metcalfe,	
2008	and	Komi,	2017).	
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Figure	4:	Stem	cell	factor	mediated	c-KIT	signalling	pathway.	SCF	mediated	c-KIT	signalling	plays	
important	roles	in	mediating	angiogenesis,	migration,	cell	survival	and	proliferation	of	mast	cells	
(Figure	adapted	from	Metcalfe,	2008	and	Komi,	2017).	
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Figure	5:	Cross	linking	of	IgE	bound	allergen	and	the	FcER1	signalling	pathway	in	the	mast	cell.	
FcER1	signalling	pathway	is	associated	with	the	production	of	mediators	and	degranulation	(Figure	
adapted	from	Metcalfe,	2008	and	Komi,	2017).	
	
1.3	Mastocytosis,	Variants	and	Prevalence		
Mastocytosis	is	considered	a	rare	disease	with	various	studies	calculating	an	
estimated	incidence	of	5	to	10	new	cases	per	1	million	population	per	year	
(Hartmann	et	al.,	2001).		A	prevalence	of	1	in	60,000	was	reported	by	the	authors	
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of	an	epidemiological	study	in	Europe	and	the	United	States	(Magliacane	et	al.,	
2014).		
	
Nettleship	and	Tay	(1869)	first	described	mastocytosis	in	1869	as	a	rare	form	of	
urticaria	which	was	later	termed	urticaria	pigmentosa	by	Sanger	(Sanger,	1878).	In	
1887	Unna,	reported	an	association	between	the	lesions	and	an	increase	in	dermal	
mast	cell	numbers	(Unna,	1887).		In	1949	the	first	case	of	SM	was	reported	(Ellis,	
1949)	with	different	sub	classifications	of	cutaneous	mastocytosis	(CM)	and	
systemic	mastocytosis	(SM)	being	described	over	the	following	decades	(Valent	et	
al.,	2017).	It	has	now	been	established,	based	on	clinical	observations,	that	SM	can	
present	with	or	without	skin	lesions	and	can	display	an	indolent	or	aggressive	
clinical	course,	in	some	instances	with	co-existence	of	a	clonal	non-mast	cell	
lineage	disorder	such	as	a	myeloproliferative	disorder	or	myelodysplastic	syndrome	
(Metcalfe	et	al.,	2017).		In	current	clinical	practice	the	diagnosis	of	mastocytosis	is	
based	on	the	World	Health	Organisation	(WHO)	Criteria	developed	in	2001	and	
updated	in	2008	and	2016	(Valent,	2017).	The	WHO	diagnostic	criteria	includes	a	
classification	of	mastocytosis	based	on	molecular	markers,	haematological	findings,	
serum	tryptase	levels,	CD	markers	and	the	identification	of	associated	mutations	
(Metcalfe	et	al.,	2017).				
	
Further,	the	2016	updated	World	Health	organisation	(WHO)	classification	
discriminates	cutaneous	mastocytosis	(CM),	disease	confined	to	the	skin,	and	
systemic	variants	which	reflect	different	clinical	presentation,	prevalence	and	
outcome	(Valent	et	al.,	2017),	(Figure	6).	
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Figure	6:	The	2016	updated	WHO	classification	and	prevalence	of	Mastocytosis.	Variants	and	
prevalence	of	mastocytosis,	Systemic	Mastocytosis	and	Cutaneous	Mastocytosis.		Systemic	
mastocytosis	is	further	subdivided	into	Indolent	SM	(ISM),	Smouldering	SM	(SSM),	SM	with	
associated	hematologic	neoplasm	(SM	with	AHN),	Aggravated	SM	and	Mast	cell	leukaemia.	
Cutaneous	Mastocytosis	is	further	subdivided	into	maculopapular	CM	(MPCM),	Diffused	CM	(DCM)	
and	localised	Mastocytoma	of	the	skin	(Figure	adapted	from	Valent	et	al.,	2017	and	Magliacane	et	
al.,	2014).	
	
The	most	frequent	variants	of	mastocytosis	are	CM	and	Indolent	SM,	with	the	
rarest	found	to	be	mast	cell	leukaemia.	The	cutaneous	form	of	the	disease,	which	is	
limited	to	the	skin,	comprises	of	three	clinical	variants	including	maculopapular	CM	
(MPCM),	diffused	CM	(DCM)	and	cutaneous	mastcocytoma	(Figure	6).	All	the	
cutaneous	manifestations	are	more	common	in	children	with	80%	of	cases	
occurring	during	the	first	year	of	life.	Many	cases	spontaneously	regress	at,	or	
during,	puberty	and	are	associated	with	a	good	lifetime	prognosis	(Fried	and	Akin,	
2013).	
	
WHO	Classification	of	
Mastocytosis
Cutaneous	
Mastocytosis
Systemic	
Mastocytosis
Sub-variants Prevalence	
• Indolent SM <10%
• Smouldering SM <10%
• SM with	AHN 1%
• Aggressive	SM 5%
• Mast cell	leukemia <1%
• Mast	cell	sarcoma	 <1%
Sub-variants Prevalence	
• Maculpapular CM
• Diffuse CM 85%
• Masrocytoma of	the	
skin	
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In	contrast,	the	systemic	form	of	the	disease,	which	is	a	clonal	and	disseminated	
condition,	comprises	six	clinical	variants	including,	indolent	systemic	mastocytosis	
(ISM),	smouldering	systemic	mastocytosis	(SSM),	systemic	mastocytosis	with	
associated	hematologic	neoplasm	(SM-AHN),	mast	cell	leukaemia	(MCL)	and	mast	
cell	sarcoma	(MCS).		Systemic	mastocytosis	mainly	affects	adults,	with	a	peak	
incidence	in	adults	between	20-40	years	of	age.	Moreover	systemic	mastocytosis	is	
a	chronic	condition	associated	with	a	poorer	prognosis	than	CM	(Lykkegaard	
Anderson	et	al.,	2012).	In	systemic	mastocytosis,	epidemiological	evidence	suggests	
that	ISM	and	SM-AHN	account	for	approximately	85%	of	patients	(Lim	et	al.,	
2009b)	(Figure	6).				
	
1.4	Clinical	Features		
Mastocytosis	is	a	condition	with	a	broad,	none	specific	symptomology	related	to	
mast	cell	release	and,	in	some	cases,	multi-organ	infiltration	(Anderson	et	al.,	
2012).		Skin	symptoms	are	common	in	mastocytosis	with	urticaria	pigmentosa	
being	the	most	frequent.	Urticarial	pigmentosa	is	characterised	by	brownish-	red	
skin	lesions	and	is	a	universal	sign	of	CM	and	in	addition,	occurs	in	90%	of	SM	
patients	including	in	up	to	50%	of	patients	with	either	SM-AHNMD	or	aggressive	
SM	(ASM)	(Soter,	2000)	meaning	it	is	a	sensitive	but	non-specific	sign	of	
mastocytosis.	In	adults,	cutaneous	lesions	are	generally	<0.5cm	in	dimeter	and	
primarily	occur	on	thighs	and	trunk	(Horney	et	al.,	2008)	(Figure	7a).	In	children,	
cutaneous	lesions	are	usually	larger,	approximately	0.5cm-	3cm	in	diameter,	and	
affect	the	body,	face	and	head.	(figure	7b).		
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Figure	7:		Urticara	Pigmentosa	(Maculopapular	skin	lesions)	in	both	adult	and	paediatric	patients.	
A)	Typical	Urticara	Pigmentosa	skin	lesions	seen	in	adult	with	CM	or	SM.	B)	Typical	Urticara	
Pigmentosa	skin	lesions,	usually	larger	in	paediatric	patients:	as	a	rule,	there	is	no	SM	involvement	
(Image	from	Horney	et	al.,	2008)		
	
One	of	the	most	common	complaints	is	pruritus	initiated	by	changes	in	
temperature	(for	instance	hot	baths),	certain	foods,	physical	activity,	alcohol	or	
drugs	(Horney	et	al.,	2008,	Lykkegaard-Anderson	et	al.,	2012).		
	
Symptoms	related	to	mast	cell	activation,	degranulation	and	release	occur	in	both	
CM	and	SM	with	the	mast	cell	mediators	inducing	vasodilation,	hypotension,	
flushing,	itching	and	syncope.	Symptoms	can	vary	in	intensity,	related	to	disease	
burden	and	extent	of	mast	cell	degranulation,	from	mild	allergic	reactions	to	severe	
life	threating	anaphylaxis	and	anaphylactic	shock	(Austen,	1992).	In	addition,	mast	
cell	release	can	also	result	in	chronic	symptoms,	such	as	persistent	gastrointestinal	
complaints	(including	vomiting	and	diarrhoea),	however	these	are	less	frequent.	
Symptom	onset	may	be	initiated	by	a	range	of	factors,	such	as	drugs	or	mediated	
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via	cross	linking	of	IgE,	infection	or	emotional	stress	(Lykkegaard-Anderson	et	al.,	
2012).		
	
The	symptomology	of	mastocytosis	may	also	be	suggestive	of	the	systemic	variety	
and	include	anaemia,	thrombocytopenia,	malabsorption,	splenomegaly,	
hepatomegaly	and	bone	disease	in	the	form	of	lytic	lesions	and	pathological	
fractures	(Austen,	1992).	These	more	severe	chronic	symptoms	result	from	multi	
system	organ	infiltration	causing	secondary	organ	dysfunction	(Lykkegaard-
Anderson	et	al.,	2012)	.		
	
	1.5	Pathogenesis			
	
Initial	small	scale	studies	aimed	to	determine	if	SCF,	the	principal	human	mast	cell	
growth	factor,	was	elevated	in	mastocytosis.	When	considered	in	its	entirety	the	
evidence	is	contradictory	with	some	authors	reporting	elevated	levels	in	
mastocytotic	skin	lesions	by	immunohistochemistry,	however	later	studies	
measuring	SCF	levels	in	skin	and	blood,	by	immunoassay,	did	not	support	these	
initial	findings	in	adult	patients.	It	is	important	to	note	however	that	many	of	these	
were	small	number	series	or	case	reports.	Therefore	research	began	to	focus	on	
the	SCF	receptor,	c-KIT	(Metcalfe,	2008).	
	
In	1995,	Nagata	and	colleagues,	identified	a	point	mutation	consisting	of	a	
substitution	of	aspartate	to	valine	in	the	catalytic	domain	of	c-KIT	(ASP816VAL	or	
D816V)	in	the	peripheral	blood	of	patient	with	mastocytosis	(Komi	et	al.,	2017).	In	
1996,	the	same	mutation	was	identified	in	CM	and	ASM	in	both	skin	and	spleen	
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(Metcalfe	et	al.,	2017).		In	normal	mature	mast	cells	activation	of	the	c-KIT	receptor	
by	its	ligand,	SCF,	results	in	increased	mast	cell	proliferation,	prolonged	survival	
and	an	intense	release	in	mediators.	These	functions	are	reinforced	in	mastocytosis	
resulting	in	autocrine	activation	and	degranulation	of	the	mast	cell.	(Horney	et	al.,	
2008).	
Recent	research,	in	bone	marrow	derived	mononuclear	cells,		has	reported	that	
>80-90%	of	patients	with	SM	have	a	somatic	gain	of	function	mutation	in	the	KIT	
receptor	tyrosine	kinase	domain,	primarily	consisting	of	an	aspartic	acid	to	valine	
substitution	(D816V)	in	the	second	catalytic	domain,	causing	enhanced	survival	and	
mast	cell	proliferation	(Komi	et	al.,	2017).	Further	research	has	demonstrated	that	
in	a	subset	of	patients	mast	cell	proliferation	increases	to	such	an	extent	that	mast	
cells	may	be	detected	in	the	peripheral	circulation	(Metcalfe,	2008).	Results	from	
molecular	studies	and	clinical	profiling	support	the	contention	that	mastocytosis	
can	arise	due	to	over	activity	of	the	c-KIT	receptor	and	that	this	is	associated	with	a	
more	severe	disease	phenotype	(Metcalfe	et	al.,	2017).	While	the	D816V	mutation	
would	appear	to	be	the	most	common,	others	have	been	reported	including	
V560G,	within	the	juxtamembranne	domain	of	KIT,	the	E839K	dominant	
inactivating	mutation	and	the	rare	germ	line	mutation	F522C	(Metcalfe,	2008)	.	
Further,	other	non-specific	oncogenic	mutations	have	been	recently	identified	in	
mastocytosis	patients	including,	TET2,	a	putative	tumour	suppressor	gene	and	N-
RAS	an	oncogene	(Magliacane	et	al.,	2014).	Although	evidence	suggests	KIT	
mutations	contribute	to	the	pathogenesis	of	mastocytosis,	they	are	also	the	most	
common	additional	genetic	abnormalities	in	Acute	Myeloproliferative	Leukaemia	
(AML)	with	a	reported	incidence	ranging	from	26-	47%.	The	c-KIT	mutation	is	
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considered	a	pro	prognostic	indicator	of	AML,	hence	limiting	their	specificity	in	
clinical	practice	(Pullarkat	et	al.,	2009).		
		
In	addition,	the	pathogenesis	of	mastocytosis	is	not	limited	to	the	activation	of	the	
KIT	receptor.	Authors	have	reported	abnormal	mast	cell	apoptosis	with	a	
preponderance	to	anti-apoptosis	contributing	to	increased	cell	survival	(Komi	et	al.,	
2017).	Lange	et	al.,	(2012)	have	reported	upregulation	of	the	anti-apoptotic	protein	
Bcl-2,	in	aggressive	mastocytosis,	along	with	the	upregulation	of	Bcl-X,	another	
anti-apoptotic	protein,	in	the	bone	marrow	of	patients	with	ISM	(Lange	et	al.,	
2012).	The	role	of	programmed	cell	death	protein-1	(PD-1)	has	recently	been	
investigated	in	mastocytosis.	The	PD-1	ligand	(PD-L1)	is	expressed	on	tumour	cells	
while	the	PD-1	receptor	is	expressed	on	T	and	B	lymphocytes.	PD-L1,	expression	on	
mast	cells	has	been	reported	(Kuklinski	and	Kim,	2016),	enabling	abnormal	mast	
cells	to	evade	immune	surveillance	(Komi	et	al.,	2017).	In	their	2017	study,	
Kuklinski	and	Kim	reported	increased	expression	of	PD-L1	in	mast	cells,	by	
immunohistochemistry,	in	skin	biopsies	obtained	from	patients	with	mastocytosis,	
although	the	exact	mastocytosis	variants	were	not	reported.		These	results	are	
supported	by	other	investigators	who	have	shown	expression	of	the	PD-1	receptor	
in	clinical	samples	of	human	CM	and	in	laboratory	studies	utilising	the	human	
mastocytosis	cell	line	LAD2.		
In	addition,	intracellular	signalling	molecules,	involved	in	KIT	signalling,	have	been	
investigated	as	possible	therapeutic	targets	for	mastocytosis.	Bibi	and	colleagues	
(2014)	have	reported	increased	phosphorylation	of	AKT	in	HMC-1	cells,	a	human	
mast	cell	line	potentially	implicating	a	role	for	the	PI3	kinase	pathway	in	the	
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pathogenesis	of	mastocytosis.	These	initial	preclinical	results	have	been	supported	
by	Komi	and	colleagues	(2017)	who	have	recently	reported	increased	
phosphorylation	of	AKT	in	patients	with	KIT	D816V	SM	(Komi	et	al.,	2017).	Further	
molecular	studies	by	Chan	and	colleagues	(2013),	described	alterations	in	KIT	
mRNA	transcription	in	SM	patients	after	identifying	novel	KIT	transcripts	in	
aggressive	mast	cell	tumours	(Chan	et	al.,	2013).					
	
1.6	Diagnosis	and	the	WHO	criteria		
The	classification	and	diagnosis	of	mastocytosis	is	based	on	established	WHO	
criteria	as	developed	and	refined	in	2008	&	2016,	by	the	identification	of	neoplastic	
mast	cells	utilising	morphological,	immunophenotypic,	and/or	genetic	criteria	
(Pardanani,	2016)	The	WHO	diagnostic	criteria	are	summarised	in	Table	2.	
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Table	2:		WHO	2016	diagnostic	criteria	for	Mastocytosis.	Table	showing	major,	minor,	B	findings	
and	C	findings	criteria	for	the	diagnosis	of	mastocytosis	(Adapted	from	Metcalfe	et	al.,	2017).		
	
	
	
	
	
	
	
	
	
	
CRITERIA	 DEFINITION		
MAJOR	
CRITERION	
• Detected	in	sections	in	BM	and/or	other	extracutaneous	organs	
–	multifocal	dense	infiltrates	of	MC	(>15	MC	in	aggregates)		
MINOR	
CRITERION	
• Detected	in	sections	in	BM	or	other	extracutaneous	organs	–	
>25%	of	MC	in	the	infiltrate	are	spindle-shaped	or	have	atypical	
morphology,		
• or	of	all	MC	in	BM	aspirate	smears,	>25%	are	immature	or	
atypical.		
	 • Detection	in	blood,	BM,	or	another	extracutaneous	organ	–	A	
activating	point	mutation	at	codon	816	of	KIT		
	 • Detection	in	blood,	BM,	or	another	extracutaneous	organ	–	mast	
cells	expressing	CD25,	with	or	without	CD2,	in	addition	to	MC	
markers.		
	 • Serum	total	tryptase	>	20	ng/mL	
B	FINDINGS	 • BM	biopsy	showing	-	>30%	infiltration	by	MC	and/or	serum	total	
tryptase	level	>200	ng/mL	
	 • Signs	of	myeloproliferation	or	dysplasia	in	non-MC	lineages	but	
insufficient	criteria	for	definitive	diagnosis	of	a	haematopoietic	
neoplasm	with	normal	or	slightly	increased	blood	counts.				
	 • Hepatomegaly	without	impairment	of	liver	function,		
• and/or	palpable	splenomegaly	without	hyperplenism	
• and/or	lymphadenopathy	on	palpation	or	imaging		
C	FINDINGS		 • BM	dysfunction	manifested	by	1	or	more	cytopenias	caused	by	
neoplastic	mast	cell	infiltration.		
	 • Hepatomegaly	with	impairment	of	liver	function		
• Ascites	
• And/or	portal	hypertension	
	 • Skeletal	involvement	with	large,	osteolytic	lesions	and/or	
pathological	fractures.			
	 • Malabsorption	with	weight	loss	due	to	gastrointestinal	MC	
infiltrates	
	 • Splenomegaly	with	hypersplenism	
	 31	
Table	3:	Diagnosis	of	Mastocytosis	Variants.	Table	showing	the	WHO	diagnosis	criteria	for	
mastocytosis	variants	(Adapted	from	Metcalfe	et	al.,	2017).		
	
	
VARIANT		 DIAGNOSIS		
• CUTANEOUS	
MASTOCYTOSIS		
Typical	mast	cell	infiltrates	in	a	multifocal	or	
diffused	pattern	on	biopsy.		
	
• SYSTEMIC	
MASTOCYTOSIS		
1	major	or	1	minor	criterion,	or	at	least	3	
minor	are	present	(see	table	2)	
	
• INDOLENT	SM	 SM	and	no	C	findings,	no	sign	of	associated	
haematological	neoplasm.	(see	table	2)	
	
• SMOLDERING	SM	 ISM	but	with	2	or	more	B	findings	and	no	C	
findings.	No	sign	of	associated	
haematological	neoplasm	or	MCL.	(see	table	
2)	
	
• SM	WITH	ASSIOSIATED	
HAEMATOLOGIC	
NEOPLASM		
Meets	criteria	for	SM	and	for	an	associated	
clonal	haematological	non-mast	cell	lineage	
disorder,	lymphoma	or	other	haematological	
neoplasm	(see	table	2)		
• AGGRESSIVE	SM	 SM	with	1	or	more	C	findings.	No	evidence	of	
MCL	(see	table	2)	
	
• MAST	CELL	LEUKEMIA		 SM	and	bone	marrow	shows	diffuse	
infiltration	by	atypical,	immature	mast	cells:	
bone	marrow	aspirate	smears	show	>20%	
mast	cells.		
	
• MAST	CELL	SARCOMA		 Unifocal	mast	cell	tumour	with	no	evidence	
of	SM,	high	grade	cytology.		
	
	
1.6.1	Bone	Marrow	Histology		
As	the	bone	marrow	is	universally	involved	in	SM,	bone	marrow	aspiration	and	
examination	remains	the	diagnostic	investigation	of	choice	in	suspected	SM.	
However	histological	examination	and	identification	of	the	key	histological	
abnormalities	(dense	mast	cell	aggregates	in	the	perivascular	and/or	
paratrabecular	bone	marrow)	may	be	hampered	by	poor	uptake	of	standard	stains	
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such	as	Giemsa,	in	particular	when	mast	cell	hypergranulation	or	abnormal	nuclear	
morphology	is	present	(Pardanani,	2016).	Immunoreactive	tryptase	has	been	
reported	as	the	most	sensitive	immunohistochemical	marker	of	mastocytosis,	
however	immunohistochemical	identification	of	tryptase,	and	KIT/CD117	lacks	the	
diagnostic	specificity	to	differentiate	normal	and	abnormal	mast	cells.	The	most	
specific	immunohistochemical	marker	has	been	reported	to	be	CD30	due	to	its	
ability	to	detect	all	abnormal	mast	cells	in	patients	with	SM	(Sotlar	et	al.,	2004)	
(Figure	8).	
		
	
Figure	8:	Bone	Marrow	trephine	biopsy,	showing	a	pathognomonic	mast	cell	aggregate	comprised	
of	morphologically	a	typical	mast	cells	revelled	by	A)	Hematoxylin-eosin	stain,	B)	Tryptase	
immunostaining,	C)	c-kit	immunostaining	(Image	from	Patnaik	et	al.,	2007).	
	
1.6.2	Mast	Cell	Immunophenotyping			
Mast	cell	immunophenotyping	by	flow	cytometry	to	identify	and	quantify	cell	
surface	antigen	expression	contributes	towards	the	minor	diagnostic	criteria	set	by	
WHO.	Normal	mast	cells	usually	express	c-KIT/CD117	and	FceR1	and	the	typical	
profile	of	normal	mast	cells	is	CD117+/	FceR1+/	CD34-/CD38-
/CD33+/CD45+/CD11c+/CD71+.	It	is	also	worthy	of	note	that	myeloid	markers,	such	
as	CD14	and	CD15,	or	lymphoid	lineage	markers,	except	CD22,	are	not	expressed	
on	normal	mast	cells	(Patnaik	et	al.,	2007)	
A B C
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In	contrast,	neoplastic	mast	cell	commonly	express	the	surface	antigens	CD25	
and/or	CD2	with	at	least	one	of	these	two	counting	as	a	minor	criterion	towards	
the	diagnosis	of	SM	according	to	the	WHO	criteria,	although	CD25	may	be	a	more	
sensitive	and	specific	marker	(Horny	et	al.,	2008;	Horny	and	Valent,	2002;	Patnaik	
et	al.,	2007).		
	
1.6.3	Serum	Tryptase	Levels		
Mast	cell	derived	tryptase	has	been	shown	to	be	a	useful	disease	related	marker	in	
SM.	Mast	cell	tryptase	include	two	molecular	forms	(alpha	and	beta)	with	
designated	subtypes	alpha	1	or	2	and	beta	1,	2	or	3.	Beta	2	tryptase	is	the	
molecular	form	released	on	mast	cell	degranulation.	It	has	been	suggested	
therefore	that	circulating	levels	of	beta	2	tryptase	may	reflect	mast	cell	burden	and	
the	extent	of	mast	cell	activation	(Patnaik	et	al.,	2007).	Circulating	mast	cell	
tryptase	activity	has	been	evaluated	as	a	diagnostic	test,	which	yielded	a	diagnostic	
sensitivity	of	83%,	and	specificity	of	>98%.	In	addition,	other	groups	have	
demonstrated	that	serum	tryptase	activity	may	be	useful	in	evaluating	treatment	
aimed	to	reduce	mast	cell	numbers	in	patients	with	SM	(Payne	and	Kam,	2004	and	
Valent	et	al.,	2017).	The	specificity	of	serum	tryptase	activity	however	is	limited	
due	to	elevated	levels	being	observed	in	other	conditions	such	as	acute	myeloid	
leukaemia	(AML),	chronic	myeloid	leukaemia	(CML)	and		myelodysplastic	
syndromes	(MDS)	(Sperr	et	al.,	2009).	At	present	there	appears	to	be	no	direct	
clinical	correlation	between	the	serum	tryptase	and	occurrence	or	severity	of	
symptoms	associated	with	increased	mast	cell	degranulation	or	systemic	mast	cell	
burden	(Pardanani	et	al.,	2010).	Further,	in	patients	with	indolent	mastocytosis,	
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Paradanani	and	colleagues	(2010)		reported,	mast	cell	release	levels	were	
significantly	correlated	with	bone	marrow	burden,	but	not	to	mast	cell	mediator	
release	symptoms	for	reasons	which	remain	to	be	elucidated		(Pardanani	et	al.,	
2010).		
	
1.6.4	Molecular	Biology		
The	identification	of	KIT	D816V	mutation	fulfils	a	minor	criterion	according	to	the	
WHO	diagnostic	classification	(Metcalfe	et	al.,	2017).	With	the	use	of	sensitive	
techniques,	it	is	possible	to	demonstrate	a	somatic	mutation	in	the	coding	
sequence	of	KIT-gene	in	90%	of	adult	cases	of	SM	however,	with	the	less	sensitive	
Sanger	Sequencing,	false	negative	results	may	be	reported	(Kristensen	et	al.,	2011).	
In	a	smaller	subgroup	of	adult	patients,	where	D816V	mutation	cannot	be	
demonstrated,	other	sensitive	molecular	techniques	are	able	to	detect	other	auto	
activating	mutations	of	KIT	(Lykkegaard	Anderson	et	al.,	2012).				
	
By	drawing	all	the	diagnostic	criteria	together,	Sanchez-Munoz	and	colleagues	
(2011)	conducted	a	study	to	validate	the	WHO	diagnostic	criteria	and	reported	that	
approximately	20%	of	ISM	patients	lack	mast	cell	clusters	in	the	bone	marrow	and	
approximately	30%	exhibit	a	total	serum	tryptase	level	<20	ng/ml	(Sanchez-Munoz	
et	al.,	2011).	However,	the	sensitivity	for	detecting	morphologic	atypia,	aberrant	
CD25	and/or	CD2	expression,	or	KIT	D816V	in	bone	marrow	mast	cells	is	reported	
as	>90%	although	the	reporting	of	the	diagnostic	efficacy	of	all	the	investigations	
undertaken	is	inconsistent.	The	full	diagnostic	validation	study	however	
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demonstrates	the	importance	of	the	minor	criteria	that	form	part	of	the	WHO	
diagnostic	criteria	for	mastocytosis	(Sanchez-Munoz	et	al.,	2011).	
	
1.7	Prognosis		
In	95%	of	adult	and	paediatric	patients	with	CM	and	ISM,	life	expectancy	is	not	
reduced	and	a	favourable	prognosis	is	determined	(Horney	et	al.,	2008).	Cutaneous	
mastocytosis	mainly	occurs	in	children,	with	>50%	of	recorded	cases	occurring	in	
the	paediatric	population.	In	children,	the	majority	of	cases	spontaneously	regress	
by	the	time	the	patient	reaches	adolescence.	In	adults,	however,	CM	usually	
follows	a	chronic	course	and	only	in	a	small	number	of	patients	with	ISM	does	it	
tend	to	regress	(Horney	et	al.,	2008).	In	contrast,	the	progressive	forms	of	SM,	in	
particular	ASM	and	MCL,	are	associated	with	significant	mortality,	in	some	
instances	within	a	few	months,	with	or	without	chemotherapy	to	reduce	tumour	
burden	(Valent	et	al.,	2007).		
	
While	in	an	outcome	based	follow	up	study,	Lim	and	colleagues	(2009)	followed	
342	adult	patients	with	ISM	and	ASM.	The	authors	reported	an	overall	mean	
survival	of	198	months,	which	was	reported	not	to	be	significantly	different	from	
the	non-ISM	population	when	matched	for	age	and	sex.	In	the	ASM	group	
however,	the	prognosis	was	significantly	worse,	with	an	overall	mean	survival	of	41	
months	and	5%	of	patients	with	ASM	undergoing		leukaemic	transformation	during	
the	follow-up	period	(Lim	et	al.,	2009).	While	the	outcomes	of	the	study	are	
instructive	as	to	outcome	in	ISM	and	ASM,	the	study	is	limited	by	its	small	number	
of	subjects	and	further	subgroup	analysis.		
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1.8	Current	Treatment	and	New	Investigational	Agents			
The	treatment	of	all	categories	of	mastocytosis	involves	the	control	of	symptoms	
with	pharmacological	agents,	that	inhibit	the	action	of	mast	cell	mediators	such	as	
histamine	and	leukotrienes	(Table	4),	together	with	agents	to	treat	any	associated	
haematological	disorder	and	reduce	mast	cell	burden	(Metcalfe	et	al.,	2017).	
Therapy	should	be	individualised	to	each	patients’	clinical	presentation	and	
prognosis,	due	to	the	heterogeneous	nature	of	mastocytosis.		
	
	
Table	4:	Table	of	Mastocytosis	symptoms	and	treatments.	Treatments	include	pharmacological	
agents,	that	inhibit	the	action	of	mast	cell	mediators	(Adapted	from	Metcalfe,	2017)	
	
Symptoms		 Treatment	
Flushing,	Tachycardia,	Syncope	 Aspirin,		
Diarrhoea	 Anticholinergics,	oral	cromolyn	sodium		
Pruritus,	Flushing		 H1	and	H2	Antihistamines	
Gastric	Hypersecretion		 H2	Antihistamines	and	Proton	Pump	
Inhibitors.			
Osteoporosis		 Calcium,	Vitamin	D	and	
Bisphosphonates.	
Associated	Inflammation		 Glucocorticoids		
Systemic	anaphylaxis-like	reactions		 Epinephrine	
	
	
	
Control	of	cutaneous	symptoms	such	as	pruritus	and	flushing,	together	with	gastric	
hypersecretion	can	be	controlled	by	antihistamines	and	proton	pumps	inhibitors	
respectfully.	Corticosteroids	are	also	used	for	the	treatment	of	anaphylaxis	as	well	
as	for	the	control	of	malabsorption	and	ascites	(Worobec,	2000).	In	addition,	some	
authors	report	the	use	of	aspirin	for	the	treatment	of	flushing,	tachycardia	and	
syncope	however,	this	must	be	used	with	caution	as	it	may	trigger	vascular	
collapse,	in	some	patients,	and	exacerbate	co-existing	peptic	ulcer	disease	
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(Metcalfe	et	al.,	2017).	At	present,	chemotherapy	does	not	seem	to	have	a	role	in	
the	treatment	of	the	cutaneous	or	indolent	forms	of	mastocytosis.		
Currently,	no	standardised	treatment	regimens	have	been	documented	for	use	in	
patients	with	aggressive	forms	of	mastocytosis,	rather	treatment	for		SM-AHN,	
ASM	and	MCL	are	focused	on	management	of	any	associated	medical	conditions	
and	the	underlying	haematological	disorder	and	associated	co-morbidities	
(Hennessy	et	al.,	2004).		
	
1.8.1	Interferon	alfa	(INF-a)	
	
In	patients	with	symptomatic	aggressive	SM,	INF-a	has	shown	variable	therapeutic	
efficacy,	as	a	first	line	therapeutic	agent,	to	improve	symptoms	related	to	mast	cell	
degranulation,	decrease	mast	cell	infiltration	of	the	bone	marrow	and	improve	
mastocytosis	related	ascites,	hepatosplenomegaly,	cytopenias,	cutaneous	
symptoms	and	osteoporosis.	It	should	be	noted,	however	that	these	results	are	
derived	from	small	case	series,	and	not	randomised	controlled	trials	and	hence	
patient	selection	will	be	highly	variable,	of	subject	to	selection	bias,	and	perhaps	
contribute	to	the	variable	therapeutic	efficacy	observed	in	these	small	series.	
(Kluin-Nelemans	et	al.,	1992;	Worobec	et	al.,	1996;	Butterfield,	1998;	Lehmann	and	
Lammle,	1999).	
	
Further,	using	the	WHO	diagnostic	criteria	for	mastocytosis	as	a	guide	to	measure	
treatment	efficacy,	INFa	has	been	shown	to	be	consistently	ineffective	when	
assessed	for	frequency	of	a	major	response.	In	this	context,	a	major	response	is	
defined	as	compete	resolution	of	one	of	more	baseline	C-findings	(Table	2).	In	small	
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series	clinical	investigations,	INFa	has	been	shown	to	result	in	major	therapeutic	
response	in	only	20-30%	of	cases	(Hennessy	et	al.,	2004),	although	this	can	be	
improved	by	concomitant	administration	of	glucocorticoid	to	around	40%	
(Delaporte	et	al.,	1995).	The	poor	therapeutic	efficacy	could	be	related	to	the	fact	
that	the	optimal	duration	and	dose	of	INF-a	remains	to	be	elucidated	(Delaporte	et	
al.,	1995).		
INF-a	treatment	is	not	without	side	effects	and	complications	such	as	fever,	bone	
pain,	flu	like	symptoms,	cytopenias,	depression	and	hypothyroidism	have	been	
reported	in	up	to	50%	of	patients,	however	it	should	be	noted	that	numbers	are	
small	and	patient	selection	criteria	highly	variable	(Pardanani,	2016).	Time	to	
therapeutic	response	has	also	been	variable,	with	authors	reporting	up	to	a	year,	
and	in	some	cases	longer,	to	observe	clinical	benefit	(Pardanani,	2016).		
	
1.8.2	2-Chlorodeoxyadenosine	(Cladribine	or	2-CdA)	
	
2-Chlorodeoxyadenosine	(cladribine	or	2-CdA)	is	a	purine	nucleoside	analog	which	
has	been	shown	to	reduce	cell	proliferation	by	interfering	with	DNA	replication,	
including	in	neoplastic	mast	cells.	Small	case	series	have	reported	the	use	of	
cladribine	for	the	treatment	of	all	types	of	aggressive	mastocytosis	including	
systemic	mastocytosis.	In	a	study	of	9	patients	with	systemic	mastocytosis,	
receiving	6	courses	of	treatment,	Kluin-Nelemans	et	al.,	(2003)	reported	an	
improvement	in	clinical	symptomology	and	a	decrease	in	circulating	serum	tryptase	
levels.	The	authors	concluded	that	cladribine	may	be	a	possible	therapeutic	
regimen	for	aggressive	mastocytosis,	although	the	number	of	participants	is	too	
small	to	draw	any	significant	conclusions	or	make	a	recommendation	cladribine	use	
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as	a	therapeutic	agent	in	the	setting	of	SM.	In	addition,	cladribine	is	not	without	
significant	side	effects	and	may	induce	pancytopenia	and	immunosuppression	
(Metcalfe	et	al.,	2017).							
	
1.8.3	Imatinib	Mesylate	(IM)	
Imatinib	Mesylate	is	a	tyrosine	kinase	inhibitor	that	has	been	shown	to	inhibit	the	
phosphorylation	of	wild	type	KIT,	including	some	of	the	transmembrane	and	
juxtamembrane	KIT	mutations.	Imatinib,	however	is	ineffective	at	inhibiting	the	
phosphorylation	of	KIT	with	the	common	D816V	mutation	(Pardanani,	2016).	
Presently,	Imatinib	is	the	only	therapeutic	agent	that	has	been	approved	by	the	US	
Food	and	Drug	Administration	(FDA)	for	patients	with	SM,	without	the	KIT	D816V	
mutation,	or	when	the	KIT	phenotype	is	unknown.	Evidence	for	the	use	of	Imatinib	
however	is	still	limited.	In	a	series	of	27	patients	with	SM,	Lim	and	colleagues	
(2009)	reported	an	overall	response	rate,	irrespective	of	KIT	phenotype,	of	18%	
during	a	median	duration	of	treatment	of	19.6	months.	Response	was	defined	as	
an	improvement	in	urticarial	pigmentosa	and	a	decrease	in	bone	marrow	mast	cell	
burden.	In	this	series,	however,	subgroup	analysis	of	the	86%	of	patients	who	carry	
the	D816V	mutation	reported	an	overall	response	rate	of	17%,	compared	to	33%	in	
patients	who	do	not	carry	the	D816V	mutation.	It	should	be	noted	however	that	
the	number	of	participants	was	small	and	heavily	biased	towards	patients	carrying	
the	D816V	mutation.	However	an	earlier	study	reported	overall	response	rate	of	
36%	in	patients	with	the	D816V	mutation	(Droogendijk	et	al.,	2006).	The	difference	
may	be	due	to	patient	selection	or	the	occurrence	of	Imatinib	selective	KIT	
mutations	(Pardanani,	2016).	Therefore	current	evidence	has	shown	that	efforts	to	
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inhibit	the	mutant	D816V	KIT	with	tyrosine	kinase	inhibitors	has	been	largely	
unsuccessful,	although	results	are	variable,	and	further	molecular	and	proteomic	
profilling	is	required	to	identify	potential	new	targets	(Magliacane	et	al.,	2014)	
	
	
1.8.4	Investigational	Agents		
	
Second	generation	tyrosine	kinase	inhibitors,	such	as	Midostaurine	(PKC412),	
Dasatinib	and	Nilotinib,	may	provide	additional	therapeutic	efficacy	that	is	not	
evidence	with	current	treatment	regimens.	(Metcalfe	et	al.,	2017).		
	
Dasatinib,	in	vitro,	has	shown	efficacy	against	various	KIT	mutations	including	
D816V	and	appears	to	have	modest	activity	in	KITD816V	positive	SM	(Shah	et	al.,	
2006).	Cumulative	published	data	however,	does	not	clarify	which	subgroup	of	SM	
patients	are	likely	to	gain	the	most	benefit.		(Pardanani,	2016).		
Midostaurine	(PKC412)	also	demonstrates	activity	against	kinase	domain	KIT	
mutants	(D816V)	as	in	a	small	clinical	study,	including	patients	with	MCL	who	
harbour	the	KITD816V,	resulted	in	transient	clinical	benefit	(Growney	et	al.,	2005).	
In	addition,	midostaurine	treatment,	in	patients	with	advanced	SM,		resulted	in	
significant	improvement	in	organ	function	with	concomitant	reduction	in	mast	cell	
burden,	in	the	majority	of	patients	(Pardanani,	2016).		
Brentuximab	vedotin	is	an	antibody-drug	conjugate	directed	against	the	cell	
membrane	protein,	CD30.	CD30	is	a	member	of	the	tumour	necrosis	factor	
receptor	superfamily,	with	reported	aberrant	expression	on	neoplastic	mast	cells,	
with	preferential	expression	in	advanced	SM,	the	role	of	Brentuximab	vedotin	in	
treating	advanced	SM	is	currently	being	investigated	(Pardanani,	2016).	Recently,		
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Borate	and	colleagues	(2016)	reported	the	outcome	a	phase	2	open	label	trial,	
where	two	of	four	patients	with	advanced	SM	demonstrated	an	improvement	in	
circulating	serum	tryptase	and	improvements	in	circulating	and	bone	marrow	mast	
cell	burden	(Borate	et	al.,	2016).	It	should	be	noted	however	that	these	are	
preliminary	results	in	a	small	number	of	patients	and	that	furthermore	detailed	
clinical	evaluation	of	Brentuximab	will	require	further	study	in	a	larger	patient	
cohort.		
	
1.8.5	Splenectomy	
	
In	patients	with	ASM	or	SM-AHN,	who	present	with	massive	splenomegaly,	
splenectomy	has	been	shown	to	decrease	mast	cell	burden	aiding	the	use	of	
myelosuppressive	agents	(Metcalfe,	2008).	Previous	work	by	Friedman	and	
colleagues	(1990)	has	shown	an	improvement	in	overall	survival	(34	vs	26	months	
in	the	control	group),	however	the	authors	note	the	high	surgical	risk	associated	
with	splenectomy	(Friedman	et	al.,	1990	&	Metcalfe,	2008).		
	
1.8.6	Stem	Cell	and	Bone	Marrow	Transplantation		
In	patients	with	advanced	and	potentially	fatal	SM-AHN,	MCL	and	ASM,	stem	cell	
and	bone	marrow	transplantation,	following	ablative	chemotherapy	has	been	
proposed.	To	date,	there	is	limited	outcome	data	to	show	therapeutic	efficacy,	and	
the	data	that	has	been	published	is	contradictory	(Metcalfe,	2017).		
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Therefore,	drawing	all	the	evidence	together	for	the	different	therapeutic	options	
for	mastocytosis,	Vaes	and	colleagues	(2017)	proposed	a	treatment	algorithm	for	
Mastocytosis	as	shown	below	(Figure	9).		
	
	
Figure	9:	A	Proposed	treatment	algorithm	for	Mastocytosis	sub-variants	including:	ISM,	CM,	SSM,	
ASM,	MCL,	ASM-AHN	(Adapted	from	Vaes	et	al.,	2017.)	
	
1.9	Biomarkers		
Mastocytosis	is	a	difficult	disease	to	diagnose.	It	is	recognised	that	c-KIT	is	
implicated	in	its	pathogenesis	however	we	do	not	fully	understand	what	is	driving	
its	aetiology.	Proteomics	is	a	valuable	tool	used	to	elucidate	the	differences	in	
alterations	in	proteins	and/or	protein	expression	levels	thus	providing	a	central	
contribution	to	improve	the	knowledge	into	physiological	and	pathological	
mechanisms	(Anjo	et	al.,	2017).	By	allowing	the	identification	of	biomarkers	
capable	of	distinguishing	healthy	from	diseased	conditions,	these	approaches	are	
valuable	for	applied	and	translational	research	(Anjo	et	al.,	2017)	.			
Mastocytosis
No	Treatment		
Symptoms	
No	Symptoms		
Advanced	SM		
SSM	
ISM	or	CM	
Watch	and	Wait	
Symptomatic	
Treatment		 No	Response		
Consider:	2Cda,	
IFN,	Masitinib
In	selected	cases:	2Cda,	IFN,	PKC412	
MCL
ASM-AHN	or	MCL-
AHN	
ASM	
Polychemotherapy,	2Cda,	IFN,	PKC412,	HSCT,	
Investigational	drugs		
Treat	AHN	as	if	no	SM	and	treat SM	as	if	no	AHN	
Polychemotherapy,	2Cda,	IFN,	PKC412,	HSCT,	
Investigational drugs		
	 43	
Biomarkers	can	serve	a	variety	of	functions	when	used	in	a	clinical	content		such	as	
for	diagnosis	or	risk	stratification	(Table	5).		
	
Table	5:	Biomarker	grouping	and	their	applications.	Biomarker	grouping	types	and	their	application	
when	used	in	a	clinical	content	(Adapted	from	Biomarkers	definition	working	group,	2001)			
	
Biomarkers	 Application	
Risk	stratification	biomarkers	 Identifying	the	risk	of	disease	
development		
Screening	biomarkers	 Screening	for	subclinical	diseases		
Diagnostic	biomarkers		 Recognising	overt	diseases		
Staging	biomarkers		 Categorising	disease	severity		
Prognostic	biomarker	 Predicting	future	disease	course	and	
therapy	response	
	
	
The	use	of	biomarkers	in	improving	personised	clinical	information	relies	on	
reliable	pre-analytical	and	analytical	processing	of	clinical	samples	(Heaney	et	al.,	
2017).		
	
Mass	spectrometry	(MS)	is	a	powerful	qualitative	and	quantitative	analytical	
technique	that	is	capable	of	measuring	a	wide	verity	of	clinical	relevant	analyte	
with	high	levels	of	reproducibility,	precision	and	accuracy	and	has	a	potential	to	
extend	current	capabilities	in	biomarker	discovery,	development	and	validation	
(Heaney	et	al.,	2017).	Due	to	its	incomparable	capacity	to	analyse	the	complex	
protein	mixtures	found	in	body	fluids	and	tissues,	MS	has	become	the	method	of	
choice	in	proteomic	approaches.	The	biomarker	tryptase	for	mastocytosis	does	not	
fully	fulfil	the	characteristics	of	an	idea	biomarker	therefore,	creating	the	need	to	
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establish	and	validate	sensitive	and	specific	biomarker	for	mastocytosis	
(Crutchfield,	2016).	One	way	to	measure	biomarkers	is	via	Sequential	window	
acquisition	of	all	theoretical	Mass	spectrometry	(SWATH-MS).		
	
1.10	SWATH	–	MS		
Sequential	window	acquisition	of	all	theoretical	Mass	spectrometry	(SWATH-MS)	is	
a	data	independent	acquisition	(DIA)	approach	that	is	able	to	reliably	quantify	
significant	numbers	of	peptides	and	proteins	in	an	unbiased	manner	as	well	as	
allow	peptide	identification	and	quantification	(Kang	et	al.,	2017).		
	
Proteomic	studies	have	made	remarkable	progress	recently,	facilitated	by	the	
widespread	application	of	LC	MS/MS,	and	development	of	quantification	methods	
(Domon	and	Aebersold,	2006).	The	development	of	TOF	MS	has	enabled	many	new	
approaches	for	data	acquisition	in	proteomic	analysis	possible.	There	are	generally	
three	types	of	LC	MS/MS	strategies,	targeted	acquisition,	precursor	dependant	
acquisition	and	precursor	independent	acquisition,	in	which	the	application	of	the	
different	methods	are	dependent	on	factors	such	as	goal	of	analysis,	instrumental	
performance	and	sample	complexity	(Kang	et	al.,	2017).	
Data	dependant	acquisition	(DDA)	is	a	technique	which	typically	detects	only	the	
most	abundant	peptides	from	complex	samples	after	extensive	fractionation	
(Hopfgartner	et	al.,	2012).	Data-independent	acquisition	(DIA)	is	a	technique	in	
where	fragment	ion	information	for	all	precursor	ions	within	a	determined	mass	
range	are	acquired,	therefore	result	in	an	unbiased	precursor	ion	selection	(Tate	et	
al.,	2013).		
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One	DIA	approach	is	SWATH-MS	which	utilises	the	rapid	analysis	time	of	TOF	and	
has	enhanced	ion	detection	and	fragmentation	quality	resulting	in	improved	
reproducibility	when	compared	to	DDA	approaches	(Zhu	et	al.,	2014).	Peptide	
extraction	for	SWATH-MS	data	requires	a	spectral	reference	list	containing	
information	of	retention	time	(IRTs),	fragment	ions	and	their	relative	intensity	
which	are	used	to	extract	any	given	peptide	from	SWATH-MS/MS	maps	using	the	
fragmentation	chromatograms	(Kang	et	al.,	2017).		
The	SWATH-MS	method	uses	small	Q1	windows	enabling	better	selectivity	and	
enhanced	high	confidence	peptide	extraction	from	data	files	(Kang	et	al.,	2017).	All	
precursors	present	are	associated	with	their	fragment	ions	resulting	in	improved	
identification	specificity	and	therefore	providing	a	more	in	depth	view	of	protein	
and	peptide	species	in	a	complex	sample	(Figure	10)	(Kang	et	al.,	2017).						
	
	
Figure	10:	Schematic	of	the	SWATH-MS.	Implementation	in	applied	and	translational	research	
(Adapted	from	Anjo	et	al.,	2017)		
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SWATH-MS	has	been	applied	to	biological	samples	such	as,	urine,	serum	and	
plasma	together	with	organ	specific	tissue	(Anjo	et	al.,	2017).	The	variety	of	
potential	analytical	sample	types	suggests	that	SWATH-MS	is	a	valuable	techniques	
for	the	identification	and	validation	of	biomarkers	for	diagnostic	testing	(Anjo	et	al.,	
2017).	
	
1.11	Aims	and	Objectives		
	
AIM:	Using	SWATH-MS	to	investigate	the	underlying	mechanisms	of	disease	in	
systemic	mastocytosis.	
To	carry	out	global	discovery	of	the	proteome	of	plasma	from	peripheral	blood	of	
systemic	mastocytosis	patients	and	compare	these	to	healthy	controls.		
	
Sequential	Window	Acquisition	of	all	Theoretical	fragmentation	spectra	mass	
spectrometry	(SWATH-MS)	will	be	employed	to	generate,	in	a	single	measurement,	
a	complete	permanent	recording	of	all	the	components	in	a	biological	sample	–	a	
digital	map.		
	
The	aim	is	to	identify	proteins	that	may	discriminate	between	the	two	groups	
(patients	diagnosed	with	SM	and	healthy	controls).	A	map	of	those	differently	
expressed	proteins	in	an	unbiased	manner	will	be	produced,	allowing	the	
elucidation	of	the	molecular	mechanisms	involved	in	SM.		
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2.1	Ethics		
This	study	was	approved	by	the	NHS	Health	Research	Authority	on	the	10th	May	
2016	(London	and	City	East	Research	Ethics	Committee	(16/LO/0787).	Ethical	
approval	was	also	granted	for	this	study	by	the	Faculty	of	Science	and	Engineering	
Research	Ethics	Committee,	following	the	completion	of	an	internal	ethics	checklist	
and	application.	COSHH	and	risk	assessments	were	also	completed	before	the	
study	was	launched.	The	research	is	being	co-sponsored	by	the	United	Lincolnshire	
Hospitals	NHS	Trust,	University	of	Lincoln,	Manchester	Metropolitan	University	and	
the	University	of	Manchester.	The	study	was	funded	by	the	Mastocytosis	Charity.		
	
2.2	Subjects	
	
Fourteen	(14)	patients	with	systemic	mastocytosis	were	recruited	from	the	
Mastocytosis	clinic	at	the	United	Lincolnshire	Hospitals	NHS	Trust	and	Leicester	
Royal	Infirmary.	In	addition,	eleven	(11),	apparently	healthy,	controls	were	
recruited	from	the	staff	and	students	of	Manchester	Metropolitan	University.	
Patients	and	controls	were	recruited	over	a	30-month	period	between	January	
2016	-	June	2018,	by	the	author	and	other	members	of	the	research	team.		
Patient	inclusion	and	exclusion	criteria	are	shown	below:	
Inclusion	Criteria:	
• Male	or	female	participants	≥	18	years	old.	
• Diagnosed	with	Systemic	Mastocytosis	according	to	WHO	classification	or	
documented	Mastocytosis	based	on	histological	criteria.		
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• Able	and	willing	to	provide	written	informed	consent	prior	to	participation	
in	the	study.	
Exclusion	criteria:	
• Unable	or	unwilling	to	provide	written	informed	consent	prior	to	
participation	in	the	study.	
• Pregnant	or	currently	breast	feeding.		
• <18	years	old	
• other	haematological	malignancies		
• Patients	who	have	received	chemotherapy,	any	investigational	drug	or	
undergone	majored	surgery	<	4	weeks	prior	to	the	begging	of	the	study.		
	
2.2.1	Patient	Recruitment		
Patients	were	selected	from	either	the	Mastocytosis	database,	or	from	potential	
patients,	according	to	clinical	and/or	laboratory	suspicion	of	Mastocytosis	and	
where	a	bone	marrow	biopsy	was	indicated.	Potential	study	participants	were	
invited	take	part	by	letter	and	accompanying	patient	information	sheet,	which	was	
forwarded	at	the	same	time	as	their	appointment	letter	for	the	haematology	clinic	
(Appendix	1).	Potential	participants	were	able	to	discuss	the	study,	if	they	wished	
to	seek	further	information	or	clarification,	with	a	consultant	haematologist	at	a	
time	separate	to	their	clinic	appointment.	All	patients	recruited	to	the	study	gave	
written	informed	consent	prior	to	the	collection	of	a	peripheral	blood	sample	at	
the	antecubital	fossa	(Appendix	2)	.		
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2.2.2	Recruitment	of	Control	Subjects		
Heathy	controls	were	recruited	from	the	staff	and	students	at	the	University	of	
Lincoln	and	Manchester	Metropolitan	University.	Volunteers	were	recruited	
through	use	of	general	University	of	Lincoln	and	Manchester	Metropolitan	
University	email.	Volunteers	who	were	interested	in	taking	part	were	provided	with	
a	participant	information	sheet	(Appendix	1)	and	given	the	option	to	discuss	the	
project	further	with	the	author	or	Principal	Investigator.	Participants	were	given	a	
minimum	of	24	hours	to	consider	study	related	information	before	being	asked	to	
provide	written	informed	consent	(Appendix	3)	to	collect	a	peripheral	blood	sample	
at	the	antecubital	fossa.		
	
2.3	Experimental	Protocol		
Each	participant	was	assigned	a	unique	identity	number	ensuring	that	all	data	was	
anonymised	at	source.	The	numbers	ranged	from	LCH01-LCH09	(Lincolnshire	
Hospitals	NHS	Trust),	LRI01-LRI04	(Leicester	Royal	Infirmary)	and	MCC01-MCC09,	
MMU02	for	healthy	controls	(Manchester	Metropolitan	University).		
	
2.4	Peripheral	Blood	Collection	
A	venous	peripheral	blood	sample	was	collected	at	the	antecubital	fossa	by	a	
trained	phlebotomist.	Two	peripheral	blood	samples,	of	a	total	volume	of	
approximately	8-12ml	whole	blood	(2x	EDTA-plasma,	Vacutainer,	BD,	Oxford,	
England,	UK),	were	collected	and	processed	within	24hrs	of	collection.		
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2.5	Plasma	Sample	Preparation		
Peripheral	EDTA	blood	(1ml)	(EDTA-plasma,	Vacutainer,	BD,	Oxford,	England,	UK)	
was	centrifuged	(SIGMA	3-15KL)	at	3000	rpm	for	3	minutes	at	room	temperature.	
Plasma	was	aliquoted	(15	µl)	and	stored	frozen	at	-80°C.		
	
2.5.1	Immuno-depletion	of	plasma		
Plasma	aliquots	(15	µl)	were	thawed	on	ice	and	10	µl	added	to	Top	12	abundant	
protein	depletion	spin	columns	(Pierce,	Thermos	Scientific,	Rockford,	USA).	These	
were	vortexed	and	incubated	for	60	minutes	at	room	temperature	on	a	rotary	
mixer	at	300	rpm	(Rotor	Genie	88881002,	Thermo	Scientific,	Paisley,	UK),	followed	
by	centrifugation	at	1000	g	for	2	minutes	(Mikro	185,	Hettich,	USA).		Following	
centrifugation,	the	eluate	(500	µl)	was	transferred	to	a	Amicon	ultra	0.5ml	
centrifugal	filter	device	(Millipour,	UK)	and	centrifuged	at	14,000	g	for	30	minutes	
at	room	temperature.	The	eluate	was	discarded,	and	400µl	of	25mM	ammonium	
bicarbonate	(ACROS	Organics)	added	to	the	Amicon	ultra	0.5ml	centrifugal	filter	
device	followed	by	centrifugation	at	14,000g	for	10	minutes	at	room	temperature.	
Finally,	30µl	of	25mM	ammonium	bicarbonate	was	added	to	the	Amicon	ultra	
0.5ml	centrifugal	filter	device	which	was	then	inverted	into	2ml	Eppendorff	tubes	
and	centrifuged	at	1000g	for	2	minutes	at	room	temperate	to	elute	the	proteins.		
	
2.5.2	Protein	Quantification	of	Immuno-depleted	samples		
A	Pierce	BCA	protein	Assay	Kit,	calibrated	with	bovine	serum	albumin	(BSA),	
(Thermo	Scientific,	Rockford,	USA)	was	utilised	to	measure	the	protein	
concentration	of	the	immuno-depleted	plasma	samples,	according	to	manufactures	
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instructions.	Using	BSA	and	assay	diluent,	25mM	ammonium	bicarbonate,	eight	
standards	were	prepared	across	the	concertation	range	2000µg/µl	to	0µg/µl.	
Standard	and	immunodepleted	samples	(10µl)	were	added	to	a	96	well	flat	
bottomed	microtitre	plate	in	duplicate.	Working	reagent	(200µl)	at	a	ratio	of	50:1	
was	added	to	each	well	containing	an	aliquot	of	standard	or	sample.	The	plate	was	
incubated	for	30	mins	at	37°C	and	the	absorbance	measured	at	562nM.	A	standard	
curve	was	prepared	to	determine	the	protein	concentration	in	the	
immunodepleted	samples	against	the	BSA	standards.	In	order	to	standardise	the	
amount	of	protein	subjected	to	enzymatic	digestion,	prior	to	mass	spectrometric	
proteome	analysis,	protein	concentration	was	standardised	by	the	addition	of	an	
appropriate	volume	of	25	mM	ammonium	bicarbonate.		
	
2.5.3	Digestion	of	protein	into	peptides	
Dithiothreitol	(DTT)	(12µl	of	50mM)	(Sigma,	St	Louis,	MO,	USA)	was	added	to	the	
normalised	depleted	protein	samples	to	give	a	final	concentration	of	5mM	DTT.	
Subsequently,	sodium	deoxycholate	(DOC)	(12µl	of	10%)	was	added	(at	a	final	
concentration	of	1%	sodium	deoxycholate)	and	the	mixture	incubated	for	30	mins	
at	60°C	with	agitation	(Thermo	Mixer	C,	Eppendorph).	Following	incubation	
Iodoacetamide	(IAA)	(10µl	of	650	mM)	was	added	(final	concentration	of	50mM	
Iodoacetamide).	The	mixture	was	again	incubated	for	30	minutes	in	the	dark,	at	
room	temperature.	Following	incubation,	enzymic	digestion	was	performed	by	the	
addition	of	trypsin	(1:50	at	a	final	concentration	of	0.1	µg/µl).	The	mixture	was	
again	incubated	at	37°C,	overnight.	Equal	volumes	of	1%	formic	acid	were	then	
added	(final	concentration	of	0.5%	formic	acid)	and	the	samples	centrifuged	at	
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12,000	g	for	10	mins,	the	supernatant	transferred	into	new	clean	1.5µl	microfuge	
tubes	and	vacuum	concentrated	for	approximately	90	minutes	(Speedvac	
concentrator,	Savant	SPD1010,	Thermo	Sientific).	Samples	where	then	freeze	dried	
and	stored	frozen,	prior	to	mass	spectrometry,	at	-80°C.			
	
2.5.4	Reconstitution	of	samples		
Depleted	and	digested	samples	were	allowed	to	thaw	on	ice	and	reconstituted	to	
give	a	final	concentration	of	1µg	of	protein	per	5µl	volume,	using	3%	Acetonitrile	in	
0.1%	formic	acid	solution.	Internal	standard	at	0.1%	final	concentration	of	IRTs	was	
added	to	each	sample	(Index	retention	time,	Biognosys,	Switzerland)	(Figure	11).				
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Figure	11:	Flow	diagram	of	plasma	sample	preparation.		
	
2.6	Mass	Spectrometry			
2.6.1	Triple-	TOF	MS	analysis	and	SWATH	data	analysis		
Samples	from	each	patient	and	control	subject	were	loaded	onto	a	6600	Triple	TOF	
mass	spectrometer,	in	triplicate	(AB	Sciex,	Warrington,	UK),	with	an	Eksigent	1D+	
Nano	LC	system	(Eksigent,	Dublin,	CA)	for	SWATH-MS	analysis.	The	LC	gradient	
consisted	of	buffer	A	(2%	acetonitrile	and	0.1%	formic	acid	in	HPLC	water)	and	
buffer	B	(2%	water	and	0.1%	formic	acid	in	acetonitrile).	Protein	depleted	and	
digested	samples	were	spiked	with	1:50	(v:v)	iRT	peptides.	Sample	(5µl)	was	
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injected	(1µg	of	protein	in	5	µl	injection	volume)	and	separated	with	a	linear	
gradient	of	2%	buffer	A	to	35%	buffer	B	over	135	minutes	at	a	flow	rate	of	0.3µl	
min-1.	
	
The	mass	spectrometer	was	operated	and	data	collected	in	SWATH	acquisition	
mode	using	100	variable	windows.	SWATH	wiff	files	were	converted	into	mzXML	
files.	The	mzXML	file	was	converted	to	mzML	file	using	OpenMS	tool	File	converter.	
Spectral	alignment	and	targeted	data	extraction	of	DIA	samples	were	performed	
with	SWATH	2.0	processing	in	Peakveiw	(version	2.2,	AB	Sciex)	using	an	in-house	
reference	spectral	library.		
	
2.6.2	Processing	of	Mass	Spec	Data	
Spectral	aliment	and	targeted	extraction	of	DIA	samples	were	performed	in	
Peakview	(version	2.0,	Sciex).	DIA	raw	files	were	loaded	in	unison	using	extraction	
window	false	discovery	rate	(FDR)	of	1%	and	peptide	confidence	of	99%.	After	data	
processing,	raw	data	including	peak	area	and	retention	times	were	exported	from	
Peakveiw	to	Microsoft	Excel.	Data	was	processed	and	analysed,	using	MSStats	and	
Markerviewer	(Sciex).		
Principle	component	analysis	plots	(PCA)	were	produced	using	Markerveiwer	
(Sciex).	Volcano	plots	were	generated	using	GraphPad	Prism	7.	Data	was	expressed	
as	mean	and	the	differences	were	determined	using	Welch’s’	t	tests	to	determine	
differences	in	regulated	proteins.		A	probability	value	of	<	0.05	with	95%	
confidence	limit	was	considered	statistically	significant.	A	fold	chance	of	>1.5	was	
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reported	as	significantly	up	regulated	and	1/1.5	(<0.667)	significantly	down	
regulated.	
	
2.6.3	Bioinformatics,	Functional	and	Descriptive	analysis		
The	international	standardised	gene	function	classification	system	of	gene	ontology	
(GO)	(http://www.geneontology.org/)	and	the	Database	Annotation	Visualisation	
and	Integrated	Discovery	(DAVID)	database	were	used	to	interpret	the	biological	
processes,	molecular	functions	and	the	cellular	components	of	the	significantly	up	
regulated	identified	proteins	(P	value	<0.05),	(fold	change	>1.5).	
ClueGo	(Version	3.6.1,	a	Cytoscape	plug-in)	was	used	to	assess	proteins	that	were	
significantly	enriched	(P-value	<0.05,	fold	change	>1.5-2).	Functional	gene	ontology	
(GO)	categories	in	biology	processes	were	reported	using	right-sided	
hypergeometric	test.	Protein-protein	interactions	were	determined	using	the	
STRING	database	(version	10.5)	with	a	high	confidence	level	applied	of	0.7.			
The	PANTHER	(v.8.0)	(protein	annotation	through	evolutionary	relationship)	
classification	system	(http://www.pantherdb.org/)	was	employed	to	perform	a	
statistical	overreprentation	test	between	the	360	significantly	enriched	proteins	
identified	and	a	relative	reference	list	in	PANTHER	(Version	11.0)	using	a	test	type	
of	Fishers	exact	with	FDR	multiple	test	correlations.	Statistical	significant,	
overrepresented	proteins	were	determined	and	grouped	into	Biological	process	
and	Reactome	pathways	(P	<0.05),	(fold	change	>2.0).		
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2.7		ELISA		
	
2.7.1	C-Reactive	Protein	(CRP)	
	
CRP	was	measured	in	neat	human	plasma	using	a	SimpleStep	ELISA	kit	(Catalogue	
Number	ab181416,	Abcam	UK)	according	to	manufacturer’s	instructions.		
Briefly,	standards	in	the	range	of	0	-	1000pg/ml	were	prepared	in	sample	diluent.	
Samples	(1:10000	dilution	in	sample	diluent)	or	standards	(50µl)	were	added,	in	
duplicate,	to	each	well	of	a	coated	mictotitre	plate.	Antibody	cocktail	(50µl)	was	
added	to	each	well	and	the	plate	incubated	for	1	hour	at	room	temperature	with	
agitation.	Following	incubation,	the	plate	was	washed	(x3)	with	plate	wash	buffer	
and	blotted	dry.	Substrate	(TMB,	100µl)	was	added	to	each	well	and	the	plate	
incubated	for	10	minutes,	with	agitation,	at	room	temperature	in	the	dark.	
Following	incubation,	stop	solution	(100µl)	was	added	and	the	OD	at	450nm	
measured	on	a	plate	reader.		
	
2.7.2	Beta-2	Microglobulin	(b2M).		
b2M	was	measured	in	neat	human	plasma	using	a	SimpleStep	ELISA	kit	(Catalogue	
Number	ab181423,	Abcam	UK)	according	to	manufacturer’s	instructions.		
Briefly,	standards	in	the	range	of	0	–	2000	pg/ml	were	prepared	in	sample	diluent.	
Samples	(1:10000	dilution	in	sample	diluent)	or	standards	(50µl)	were	added,	in	
duplicate,	to	each	well	of	a	coated	mictotitre	plate.	Antibody	cocktail	(50µl)	was	
added	to	each	well	and	the	plate	incubated	for	1	hour	at	room	temperature	with	
agitation.	Following	incubation,	the	plate	was	washed	(x3)	with	plate	wash	buffer	
and	blotted	dry.	Substrate	(TMB,	100µl)	was	added	to	each	well	and	the	plate	
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incubated	for	10	minutes,	with	agitation,	at	room	temperature	in	the	dark.	
Following	incubation,	stop	solution	(100µl)	was	added	and	the	OD	at	450nm	
measured	on	a	plate	reader.		
	
2.7.3	Platelet	Basic	Protein	(CXCL7)		
	
CXCL7	was	measured	in	neat	human	plasma	using	a	SimpleStep	ELISA	kit	
(Catalogue	Number	ab216171,	Abcam	UK)	according	to	manufacturer’s	
instructions.	Briefly,	standards	in	the	range	of	0	-	300	pg/ml	were	prepared	in	
sample	diluent.	Samples	(1:10000	dilution	in	sample	diluent)	or	standards	(50µl)	
were	added,	in	duplicate,	to	each	well	of	a	coated	microtitre	plate.	Antibody	
cocktail	(50µl)	was	added	to	each	well	and	the	plate	incubated	for	1	hour	at	room	
temperature	with	agitation.	Following	incubation,	the	plate	was	washed	(x3)	with	
plate	wash	buffer	and	blotted	dry.	Substrate	(TMB,	100µl)	was	added	to	each	well	
and	the	plate	incubated	for	10	minutes,	with	agitation,	at	room	temperature	in	the	
dark.	Following	incubation,	stop	solution	(100µl)	was	added	and	the	OD	at	450nm	
measured	on	a	plate	reader.		
	
2.7.4	Transforming	Growth	Factor	Beta	1	(TGFb1)	
	
TGFb1	was	measure	in	neat	plasma	using	a	TGF	beta	1	Human	ELISA	KIT	(Catalogue	
Number	ab216171,	Abcam	UK)	according	to	manufactures	instructions.	Briefly,	
standards	ranged	from	0	-	4000	pg/ml	were	prepared	in	sample	diluent.	Samples	
(1:4	dilution	in	sample	diluent)	or	standards	(100µl)	were	added,	in	duplicate,	to	
each	well	of	a	coated	microtitre	plate.	The	plate	was	incubated	overnight	at	4oC	
with	gentle	agitation.	Following	incubation,	the	plate	was	washed	(x4)	with	wash	
	 59	
buffer	and	blotted	dry.	Biotinylated	TGF	beta	1	Detection	Antibody	(100µl)	was	
added	to	each	well	and	the	plate	was	incubated	for	1	hour	at	room	temperature	
with	gentle	agitation.	Following	incubation,	the	plate	was	washed	(x4)	with	wash	
buffer	and	blotted	dry	before	the	addition	of	HRP-	Streptavidin	solution	(100µl)	to	
each	well.	The	plate	was	incubated	for	a	further	45	minutes	at	room	temperature	
with,	gentle	agitation,	before	the	plate	was	once	again,	washed	(x4)	with	wash	
buffer	and	blotted	dry.	Substrate	(TMB,	100µl)	was	added	to	each	well	and	the	
plate	incubated	for	30	minutes,	with	agitation,	at	room	temperature	in	the	dark.	
Following	incubation,	stop	solution	(100µl)	was	added	and	the	OD	at	450nm	
measured	on	a	plate	reader.		
	
2.7.5	Liposaccharide	Binding	Protein	(LBP)	
	
LBP	was	measured	in	neat	plasma	using	Human	LBP	ELISA	KIT	(Catalogue	Number	
ab213805,	Abcam	UK)	according	to	manufactures	instructions.	Briefly,	standards	
ranged	from	0	-	50ng/ml	were	prepared	in	sample	diluent.	Samples	(1:100	dilution	
in	sample	diluent)	and	standards	(100µl)	were	added,	in	duplicates,	to	each	well	of	
a	coated	microtitre	plate.	The	plate	was	then	incubated	at	37	oC	for	90	minutes,	
before	the	contents	of	the	plate	were	discarded	and	biotinylated	anti-human	LBP	
antibody	working	solution	(100µl)	added	to	each	well.	The	plate	was	then	
incubated	at	37	oC	for	60	minutes	before	being	washed	(x3)	with	0.01	M	PBS.	
Avidin-Biotin-Peroxidase	Complex	working	solution	(100µl)	was	added	to	each	well	
and	incubated	at	37	oC	for	30	minutes.	The	plate	was	washed	again	(x5)	before	
substrate	(TMB,	90µl)	was	added	to	each	well	and	the	plate	incubated	for	30	
	 60	
minutes,	at	37	oC,	in	the	dark.	Following	incubation,	stop	solution	(100µl)	was	
added	and	the	OD	at	450nm	measured	on	a	plate	reader.		
	
	
2.7.6	Platelet	derived	growth	factor	receptor	Beta	(PDGFrb)	
	
PDGF	Receptor	Beta	was	measured	in	neat	plasma	using	a	PDGF	receptor	beta	
Human	ELISA	KIT	(Catalogue	Number	ab100626,	Abcam	UK)	according	to	
manufactures	instructions.	Briefly,	standards	ranged	from	0	-	18,000	pg/ml	were	
prepared	in	sample	diluent.	Samples	(1:20	dilution	in	sample	diluent)	or	standards	
(100µl)	were	added,	in	duplicates,	to	each	well	of	a	coated	microtitre	plate.	The	
plate	was	incubated	overnight	at	4oC	with	gentle	agitation.	Following	incubation,	
the	plate	was	washed	(x4)	with	wash	buffer	and	blotted	dry.	Biotinylated	PDGF	
receptor	beta	Detection	Antibody	(100µl)	was	added	to	each	well	and	the	plate	
incubated	for	1	hour	at	room	temperature	with	gentle	agitation.	Following	
incubation,	the	plate	was	washed	(x4)	with	wash	buffer	and	blotted	dry	before	the	
addition	of	HRP-	Streptavidin	solution	(100µl)	to	each	well.	The	plate	was	
incubated	for	a	further	45	minutes	at	room	temperature	with,	gentle	agitation,	
before	being,	washed	(x4)	with	wash	buffer	and	blotted	dry.	Substrate	(TMB,	
100µl)	was	added	to	each	well	and	the	plate	incubated	for	30	minutes,	with	
agitation,	at	room	temperature	in	the	dark.	Following	incubation,	stop	solution	
(100µl)	was	added	and	the	OD	at	450nm	measured	on	a	plate	reader.		
	
All	data	was	uploaded	to	a	master	Microsoft	Office	Excel	spreadsheet	(Microsoft	
Excel	for	Mac,	Version	15.30)	pending	analysis.	For	statistical	analysis,	data	was	
imported	into	Prism	7	for	Mac	(GraphPad	Software,	California,	USA).	Parametric	
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(Independent	T	test)	tests	were	used	to	compare	systemic	mastocytosis	patients	
and	healthy	control	results.	Graphical	outputs	and	box	and	whisker	plots	were	
produced	using	Prism	7	for	Mac	(GraphPad	Software,	California,	USA).	A	P<0.05	
was	accepted	as	statistically	significant.		
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Chapter	3:	Results	
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3.1	Study	participants		
	
A	total	of	thirteen	healthy	controls,	three	from	University	of	Lincoln	and	ten	from	
Manchester	Metropolitan	University,	were	invited	to	participate	in	the	study,	
which	resulted	in	eleven	participants	attending	the	first	enrolment	visit.	From	the	
enrolment	visit,	four	were	excluded	due	to	poor	venous	access,	meaning	a	total	of	
seven	healthy	controls	were	included	in	the	proteomic	analysis	by	mass	
spectrometry	(Figure	12).			
Fourteen	patients	with	Systemic	Mastocytosis,	who	were	attending	the	
Mastocytosis	clinics	at	the	United	Lincolnshire	Hospitals	NHS	Trust	and	Leicester	
Royal	Infirmary,	were	also	invited	to	participate.	In	total,	thirteen	patients	with	
systemic	mastocytosis	were	included	in	the	proteomic	analysis	by	mass	
spectrometry,	with	one	patient	sample	excluded	due	to	gross	haemolysis	(Figure	
12).				
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Figure	12:	Study	Flow	Diagram.	Flow	diagram	showing	initial	recruitment	of	Systemic	Mastocytosis	
patients	and	Controls.	Diagram	also	shows	the	number	of	participants	excluded	(patients	and	
controls).	The	main	reasons	for	exclusion	of	participants	was	poor	venous	access	and	sample	
haemolysis.		
	
3.2	Table	of	participant	Characteristics	
	
Participants	demographics	are	shown	in	table	6	below.	There	was	a	greater	number	
of	female	participants,	9	from	the	systemic	mastocytosis	patient	group	and	1	from	
the	healthy	control	group,	however	the	gender	of	4	participants	is	unknown.	The	
mean	age	of	the	healthy	control	group	is	44	years	compared	to	58	years	in	the	
patients	group	(P	>0.05).	A	point	mutation	consisting	of	a	substitution	of	aspartate	
Initial	contact	via	email	or	
via	letter
(n=27)
(SM	patients=14)
(Controls=13)
In-person	 enrollment	visit
(n=24)
(SM	patients=14)
(Controls=11)
Enrolled	
(n=24)
(SM	patients=14)
(Controls=11)
Tested	and	Analysed	
(n=20)
(SM	patients=13)
(Controls=7)
Excluded	(controls:	n=2)
• Did	not	 respond	to	initial	
contact
• Other	undisclosed	reasons	
Excluded	(controls:	n=4,	
patients:	n=1)
• Due	to	poor	venous	
access
• Due	to	gross	
haemolysis	
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to	valine	in	the	catalytic	domain	of	c-KIT	(ASP816VAL	or	D816V)	was	detected	in	
the	peripheral	blood	of	9,	out	of	the	13,	patients	diagnosed	with	systemic	
mastocytosis.	KIT	status	was	not	determined	in	the	healthy	control	group.	Patients	
diagnosed	with	systemic	mastocytosis	had	a	mean	serum	tryptase	of	92ng/ml.	
Healthy	control	participants	had	higher	mean	haemoglobin	(138g/l)	compared	to	
patients	diagnosed	with	systemic	mastocytosis	(129g/l),	although	the	difference	
did	not	reach	the	level	of	statistical	significance.	The	patient	group	had	a	higher	
white	cell	count	and	platelet	count	(6.37	x	109/L,	245	x	109/L)	when	compared	to	
the	healthy	control	group	(5.53	x	109/L,	169	x	109/L),	which	again	did	not	reach	the	
level	of	statistical	significance.	
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Table	6:		Table	of	participants’	characteristics.	Demographics	include	age,	gender,	kit	status,	
Tryptase	(ng/ml),	Haemoglobin	(g/l),	white	cell	count	(WCC,	x109/L),	platelets	(x109/L).				
	
Characteristic	 Systemic	
Mastocytosis	
Patients	
Healthy	Controls	 Total	
Participants	
Subjects	(n)	
	
13		 7	 20	
Age	(median[range])	
	
58	[27-80]	 44	[26-55]	 51	[26-80]	
Gender	
	
	
	
Male	=	3	
Female	=	9	
Unknown	=	1	
	
Male	=	3	
Female=	1	
Unknown	=	3	
Male	=	6	
Female	=	10	
Unknown	=	4	
Kit	Status	
	
	
	
Positive	=	9	
Negative	=	1	
Unknown	=	3	
-	 Positive	=	9	
Negative	=	1	
Unknown	=	3	
Tryptase	(ng/ml)	
(mean	[range])	
	
92	[20.5->200]	 -	 92	[20.5-
>200]	
Haemoglobin	(g/l)	
(mean	[range])	
	
129	[91-155]	 138	[124-142]	 133.5	[91-155]	
WCC	(10x109/L)	
(mean	[range]) 
	
6.37	[2.5-9.5]	 5.53	[2.25-5.99]	 5.59	[2.25-9.5]	
Platelets	(10x109/L)	
(mean	[range])	
	
245	[112-362]	 169	[135-205]	 207	[112-205]	
	
	
3.3	Gel	Electrophoresis	showing	the	depletion	and	digestion	of	Plasma	
samples	
	
Prior	to	tryptic	digestion,	plasma	samples	were	immunodepleted	to	remove	high	
abundance	proteins	(Table	7).	Previous	work	has	shown	that	immunodepletion	and	
tryptic	digestion	are	necessary	to	improve	the	overall	accuracy	and	precision	of	
proteomic	analysis	(Pan,	et	al	2009).	In	order	to	assess	the	efficiency	of	this	step,	
immunodepleted	and	digested	samples	were	subject	to	SDS-polyacrylamide	gel	
electrophoresis.	Figure	13	shows	the	results	of	Immunodepletion	and	tryptic	
	 67	
digestion.	As	can	be	observed,	Immunodepletion	removed	the	majority	of	the	high	
abundance	proteins,	mainly	albumin,	while	tryptic	digestion	resulted	in	the	
fragmentation	of	proteins	into	peptides.		
	
	
	
Table	7:	List	of	the	top	12	proteins	removed	by	Pierce	top	12	abundant	protein	depletion	
spin	columns	(Pierce,	Thermos	Scientific,	Rockford,	USA).				
	
Top	12	Proteins	Removed	by	Depletion	Spin	Columns	
Alpha	1-	Acid	Glycoprotein	
Alpha	1-	Antitrypsin	
Alpha	2-	Macroglubulin	
Albumin	
Apolipoprotein	A-I	
Apolipoprotein	A-II	
Fibrinogen	
Haptoglobin		
IgA	
IgG	
IgM	
Transferrin	
	
	
	
	
	
	
	
	 68	
	
	
Figure	13:		SDS-Polyacrylamide	Gel	Electrophoresis.	This	figure	shows	an	image	of	a	gel	post	
electrophoresis	using	control	sample.	Pre	Immunodepleted	plasma	(5µl)	diluted	1:10/	Post	
immunodepleted	sample,	pre-trypsin	digest	–	20µg	/Post	Trypsin	digested	sample.		Left	hand	lane	
showing	SeeBlue	Plus2	pre-stained	protein	molecular	weight	standards	(molecular	weight	range	3-
198	kDa)	(Thermos	Scientific	–	UK).			
	
	
3.4	Proteome	difference	between	patients	and	controls	
	
Principle	component	analysis	(PCA)	was	undertaken	to	show	the	proteomic	
differences	between	the	systemic	mastocytosis	patients	and	healthy	controls.	
Figure	14	demonstrates	that	mastocytosis	patients	can	be	clearly	separated	on	
proteomics	from	the	healthy	control	population.	
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Figure	14:	Principle	component	analysis	of	Systemic	Mastocytosis	patents	and	Control	samples.		
	
	
	
	
3.5	Proteins	identified	and	the	Profile	of	the	Significantly	Enriched	Proteins	
	
A	high-level	coverage	of	plasma	proteome	was	achieved	with	a	total	of	1437	
proteins	being	identified	at	a	1%	FDR	and	99%	peptide	confidence.	A	table	
including	all	1437	proteins	identified,	along	with	their	individual	P	and	fold	change	
values,	was	constructed	and	is	available	in	Appendix	5.	
	A	volcano	plot	was	constructed	to	show	the	results	of	the	differentially	expresses	
proteins,	between	the	patient	and	control	groups,	based	on	fold	change	versus	t-
test	probability	as	shown	in	Figure	15.		
Masto Patients	
Controls	
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When	considering	patients	with	Systemic	Mastocytosis,	368	(of	the	1437)	proteins	
were	found	to	be	significantly	differentially	expressed	(>1.5	&	<	1/1.5-fold	change)	
when	compared	to	the	control	population	(P	<	0.05).	Of	the	proteins	identified,	360	
were	found	to	be	significantly	up	regulated,	in	patients,	with	a	>1.5-fold	change,	
and	8	found	to	be	significantly	down	regulated,	in	patients,	with	a	fold	change	
<1/1.5	(<0.667),	when	compared	to	apparently	healthy	controls.	A	table	of	all,	360	
significantly	upregulated	and	8	significantly	down	regulated	proteins	identified,	
along	with	their	individual	P	value	and	fold	change,	was	constructed	and	is	
available	in	Appendix	6	&	7.	Significantly	up	regulated	proteins	included,	C-reactive	
protein	(CRP),	Transforming	Growth	Factor	Beta	1	(TGFb1),	Beta	2	Microglobulin	
(b2M),	Colony	Stimulating	Factor	1	Receptor	(CSF1R)	and	Vascular	Endothelial	
Growth	Factor	Receptor	1	Precursor	(FLT1)	are	represented	as	red	dots	seen	in	
Figure	15.		
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Figure	15:	Volcano	plot	showing	differentially	expressed	proteins.	The	volcano	plot	shows	the	
results	of	differentially	expressed	proteins	between	patient	and	healthy	control	groups,	based	on	
fold	change	versus	t-test	probability.	Each	protein	is	represented	as	a	black	dot	and	is	mapped	
according	to	its	fold	change	on	the	abscissa	axis	(x)	and	t-test	p-value	on	the	ordinate	axis	(y).	Any	
proteins	with	a	P	<0.05	are	found	to	have	significant	changes	when	compared	to	controls	(above	
horizontal	red	line).	Any	proteins	found	to	have	a	fold	change	of	<	0.667	was	considered	
downregulated	when	compared	to	controls	(left	of	red	vertical	line).	Proteins	found	to	have	a	fold	
change	of	>	1.5	were	considered	up	regulated	when	compared	to	control	group	(right	of	red	vertical	
line).	Significantly	up	regulated	proteins	included,	C-reactive	protein	(CRP),	Transforming	Growth	
Factor	Beta	1	(TGF1),	Beta	2	Microglobulin	(B2M),	Colony	Stimulating	Factor	1	Receptor	(CSF1R),	
Vascular	endothelial	growth	factor	receptor	1	precursor	(FLT1)	(marked	as	red	dots	above).	
		
	
In	order	to	explore	protein-protein	interactions,	STRING	(Version	10.5),	protein-
protein	interaction	(PPI)	network	analysis	was	performed	at	a	high	confidence	
score	of	0.7	as	illustrated	below	in	figure	16.	The	results	demonstrated	a	significant	
association	amongst	the	significantly	up	regulated	proteins.	
Further,	PPI	network	analysis	(Figure	16)	suggests	the	identified	proteins	have	
strong	interactions	that	contribute	to	numerous	biological	functions	including,	
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complement,	proteasomes,	protein	synthesis	and	degradation,	inflammation	and	
immune	Response,	DNA	repair	and	increased	cell	survival,	enhanced	protein	
folding,	platelet	aggregation	and	activation	and	the	TGF-b	pathway.	This	suggests	a	
general	state	of	pro-inflammatory	and	immune	response	in	the	pathophysiology	of	
systematic	mastocytosis.		
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Figure	16:	Figure	showing	the	protein-protein	interactions	for	the	upregulated	proteins	identify	by	
SWATH-MS,	analysed	by	STRING	(Version	10.5)	with	a	high	confidence	of	0.7.	In	the	network	
analysis,	the	up	regulated	expressed	proteins	were	represented	as	nodes.			
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3.6	Functional	Annotation	of	the	Identified	Proteins		
	
To	assess	the	biological	functions	of	the	significantly	upregulated	proteins,	ClueGo	
(Version	3.6.1,	a	Cytoscape	plug-in)	and	DAVID	databases	were	utilised.	When	
analysed	for	biological	processes	it	was	revealed	that	the	identified	enriched	
proteins	are	largely	involved	in	metabolic	processes	(35%),	immune	responses	
(29%),	regulation	of	development	processes	(9%),	cell	adhesion	and	migration	(5%)	
and	cell	surface	receptor	signalling	pathways	(3%)	(Figure	17).	
		
	
	
Figure	17:	Pie	chart	representing	biological	processes	of	significantly	up	regulated	proteins	
(ClueGo,	Version	3.6.1,	a	CytoScape	plug-in).	The	biological	processes	of	the	significantly	up	
regulated	protein	were	grouped	into	metabolic	response	(35%),	Immune	response	(29%),	
Regulation	of	development	process	(9%),	Cell	adhesion	and	migration	(5%),	Cell	surface	receptor	
signalling	pathway	(3%)	and	other	(19%).		
	
	
Based	on	functional	analysis,	the	significantly	up	regulated	proteins	seem	to	
function	largely	in	the	immune	response	(29%),	which	could	be	further	sub-divided	
into	immune	effector	process	(13.79%),	leukocyte	mediated	immunity	(13.79%)	
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and	defence	response	(1.72%).	According	to	the	KEGG	pathway	annotation,	
significantly	up	regulated	proteins,	involved	with	the	immune	response	(29%),	
were	classified	into	50	pathways	(Figure	18).		
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Figure	18:	KEGG	pathway	analysis	of	significantly	up	regulated	proteins	found	in	the	immune	
response.	Many	of	the	identified	up	regulated	proteins	exhibited	biological	functions	in	relation	to	
immune	system	processes	and	response.	The	horizontal	bars	represent	the	number	of	differentially	
expressed	proteins	involved	with	various	pathways	(ClueGo,	Version	3.6.1,	a	CytoScape	plug-in).		
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Among	the	360	significantly	enriched	proteins,	147	proteins	were	found	to	be	
involved	with	immune	system	process,	54	in	the	innate	immune	response,	234	in	
response	to	stimuli,	62	in	the	regulation	of	immune	response,	90	in	defence	
response,	148	in	response	to	stress,	63	in	neutrophil	degranulation,	73	in	regulated	
exocytosis	and	87	in	leukocyte	activation	(Figure	18).	From	these	pathways,	specific	
proteins	were	identified	using	KEGG	pathway	analysis	and	the	names	of	the	specific	
proteins	may	be	found	in	table	8.	The	list	of	pathway	specific	proteins	was	
interrogated	by	visual	inspection	to	identify	proteins	common	to	the	five	pathways	
(immune	system	process,	innate	immune	response,	response	to	stimuli,	defence	
response	and	leukocyte	response)	(Table	8).	Proteins	common	to	all	pathways	are	
highlighted	in	bold	(Table	8)	and	proteins	identified	as	upregulated	by	mass-
spectrometry	were	verified	by	ELISA.		
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Table	8:	KEGG	pathways	found	in	immune	response	along	with	the	enriched	proteins.	These	
pathways	include	immune	system	process,	innate	immune	response,	response	to	stimulus,	defence	
response	and	leukocyte	activation.	Proteins	emboldened,	such	as	Beta	2	Microglobulin	(B2M),	C-	
Reactive	Protein	(CRP),	Transforming	Growth	Factor	Beta	1	(TGFb1),	Vascular	Endothelial	Growth	
Factor	receptor	1	precursor	(FLT1),	Platelet	basic	protein	(PPBP/CXCL7)	and	lipopolysaccharide	
binding	protein	(LBP)	are	consistently	found	throughout	(ClueGo,	Version	3.6.1,	a	CytoScape	plug-
in).		
	
3.7	PANTHER	–	Descriptive	Statistics		
	
A	statistical	over-representation	test	was	preformed	between	the	360	significantly	
enriched	proteins	identified	and	a	relative	reference	list	in	PANTHER	(Version	11.0)	
using	a	test	type	of	Fisher’s	exact	test	with	FDR	multiple	test	correlations.	
Immune	
System	Process
• ACTR2,	ADA,	AGA,	AGL,	ANG,	ANXA2,	ANXA3,	AP1B1,	APEH,	APP,	ARHGAP45,	ARPC5,	ATP11B,	B2M,	C1QA,	C1QC,	CAMK2B,	CAND1,	CCL15,	CD5L,	CFHR5,	
CPNE1,	CRIP1,	CRP,	CSF1R, CTSA,	CTSF,	DDX17,	DMBT1,	DNM2,	DSC1,	ELANE,	ERAP2,	EXOSC4,	EZR,	FLT1, FTH1,	FTL,	GPNMB,	GPX1,	GUSB,	H3F3A,	HBB,	
HLA-B,	HLA-DRA,	HMGB2,	HMGB3,	HPRT1,	IGHA1,	IGHA2,	IGHG1,	IGHG2,	IGHG3,	IGHG4,	IGHM,	IGHV3-33,	IGHV3-48,	IGHV3-7,	IGHV4-34,	IGKC,	IGKV1-16,	
IGKV2-30,	IGKV3-20,	IGLV3-19,	IGLV3-21,	IGLV3-25,	IPO7,	IQGAP2,	JCHAIN,	JUP,	KRT16,	LAMTOR3,	LBP,	LDLR,	LRG1,	MANBA,	MAPK14,	MATR3,	MBL2,	MBP,	
MGAM,	MME,	MMP9,	NAPRT,	NCF4,	NOTCH2,	NT5C3A,	ORM1,	PF4,	PGAM1,	PGLYRP1,	PIGR,	PIP4K2A,	PKM,	PLCG1,	PLEK,	PNP,	POTEF,	PPBP,	PPIA,	
PPP1R14B,	PRCP,	PRDX6,	PRG2,	PRSS2,	PSMA2,	PSMA3,	PSMA5,	PSMB6,	PSMB7,	PSMC3,	PSMD1,	PSMD5,	PSME2,	PTK2,	PTPRJ,	PXDN,	PYGB,	PYGL,	RAB7A,	
RPL30,	RPS24,	RPSA,	S100A11,	S100A7,	S100A8,	S100A9,	SAA1,	SERPINB3,	SLC3A2,	STK10,	TCN1,	TFRC,	TGFB1,	THBS1,	THY1,	TIMP1,	TMOD3,	TNK2,	
TRIM25,	TRIM28,	TUBB,	TXNDC5,	UBE2N,	VCAM1, VNN1,	XRCC6
Innate	Immune	
Response	
•ANG,	APP,	B2M,	C1QA,	C1QC,	CAMK2B,	CCL15,	CFHR5,	CSF1R,	DMBT1,	HLA-B,	HLA-DRA,	HMGB2,	HMGB3,	IGHA1,	
IGHA2,	IGHG1,	IGHG2,	IGHG3,	IGHG4,	IGHM,	IGKC,	IPO7,	JCHAIN,	KRT16,	LBP,	MATR3,	MBL2,	PGLYRP1,	PPP1R14B,	
PSMA2,	PSMA3,	PSMA5,	PSMB6,	PSMB7,	PSMC3,	PSMD1,	PSMD5,	PSME2,	PTK2,	RPSA,	S100A7,	S100A8,	S100A9,	
SAA1,	TGFB1,	TNK2,	TRIM25,	TRIM28,	TUBB,	UBE2N,	VCAM1,	VNN1,	XRCC6
Response	to	
Stimulus
• ACTR2,	ACY1,	ADA,	AGA,	AGL,	AK3,	ANG,	ANGPTL3,	ANXA2,	ANXA3,	APEH,	APP,	AQR,	ARHGAP45,	ARPC5,	ATP11B,	ATP6V1A,	B2M,	B4GAT1,	C1QA,	C1QC,	
CA3,	CAMK2B,	CAND1,	CCL15,	CD5L,	CDH6,	CDK5RAP3,	CENPF,	CFHR5,	CFL1,	CGREF1,	CHGB,	CHORDC1,	CLIC4,	COL18A1,	CPNE1,	CRIP1,	CRP,	CSF1R,	CTSA,	
DDX17,	DDX5,	DMBT1,	DNM2,	DPYSL2,	DSC1,	EEF1G,	EFEMP1,	EHD1,	EIF4A2,	EIF4E,	EIF5A,	ELANE,	ENG,	ENO1,	ENTPD5,	EPN1,	ERAP2,	EXOSC4,	EZR,	FABP1,	
FAM3C,	FAP,	FKBP4,	FLNB,	FLT1,	FSTL1,	FTH1,	FTL,	GABARAPL2,	GFAP,	GMPR,	GNA13,	GPD1,	GPNMB,	GPX1,	GSS,	GTF2F1,	GUSB,	H3F3A,	HBA1,	HBB,	HBD,	
HCFC1,	HLA-B,	HLA-DRA,	HMGB2,	HMGB3,	HNRNPK,	HNRNPM,	HPRT1,	HSPE1,	IGFBP6,	IGHA1,	IGHA2,	IGHG1,	IGHG2,	IGHG3,	IGHG4,	IGHM,	IGHV3-33,	
IGHV3-48,	IGHV3-7,	IGHV4-34,	IGKC,	IGKV1-16,	IGKV2-30,	IGKV3-20,	IGLV3-19,	IGLV3-21,	IGLV3-25,	IPO7,	IQGAP2,	JCHAIN,	JUP,	KRT16, LACRT,	LAMTOR3,	
LBP,	LDHA,	LDLR,	LIMS1,	LRG1,	LTBP4,	MANBA,	MAPK14,	MATR3,	MBL2,	MBP,	ME1,	MELTF,	MGAM,	MME,	MMP9,	NAPRT,	NASP,	NCF4,	NOTCH2,	NT5C3A,	
NUP50,	ORM1,	P4HB,	PAM,	PDGFRB,	PDIA6,	PF4,	PFN1,	PGAM1,	PGLYRP1,	PIGR,	PIK3C2B,	PIP4K2A,	PKM,	PLCG1,	PLEK,	PNP,	POTEF,	PPBP,	PPIA,	PPP1CC,	
PPP1R14B,	PPP2R1A,	PRCP,	PRDX2,	PRDX6,	PRG2,	PRSS2,	PSMA2,	PSMA3,	PSMA5,	PSMB6,	PSMB7,	PSMC3,	PSMD1,	PSMD5,	PSME2,	PTGR1,	PTK2,	PTPRJ,	
PXDN,	PYGB,	PYGL,	RAB7A,	RASGRP2,	RDX,	ROCK2,	RPL30,	RPLP0,	RPSA,	RSU1,	RTN4,	S100A10,	S100A11,	S100A6,	S100A7,	S100A8,	S100A9,	SAA1,	SAA2,	
SEPT6,	SERPINB3,	SLC3A2,	SLC9A3R1,	SMPD4,	SORD,	SPTBN1,	STK10,	TARDBP,	TCN1,	TFRC,	TGFB1, THBS1,	THY1,	TIMP1,	TMSB4X,	TNK2,	TPP1,	TRIM25,	
TRIM28,	TUBB,	TXN,	TXNDC5,	UBE2N,	UBE2V2,	UCHL5,	VCAM1,	VDAC1,	VNN1,	VPS29,	XPO1,	XRCC6,	YWHAB,	YWHAZ
Defence	
Responce	
•ADA,	ANG,	ANXA3,	APP,	B2M,	C1QA,	C1QC,	CAMK2B,	CCL15,	CD5L,	CFHR5,	CPNE1,	CRP,	CSF1R, DDX17,	DMBT1,	EIF4E,	ELANE,	
EXOSC4,	GPX1,	HLA-B,	HLA-DRA,	HMGB2,	HMGB3,	IGHA1,	IGHA2,	IGHG1,	IGHG2,	IGHG3,	IGHG4,	IGHM,	IGHV3-33,	IGHV3-48,	IGHV3-
7,	IGHV4-34,	IGKC,	 IGKV1-16,	IGKV2-30,	IGKV3-20,	IGLV3-19,	IGLV3-21,	IGLV3-25,	IPO7,	JCHAIN,	KRT16,	LACRT,	LBP,	LDLR,	MAPK14,	
MATR3,	MBL2,	NT5C3A,	ORM1,	PF4,	PGLYRP1,	PPBP,	PPP1R14B,	PRCP,	PRG2,	PSMA2,	PSMA3,	PSMA5,	PSMB6,	PSMB7,	PSMC3,	
PSMD1,	PSMD5,	PSME2,	PTK2,	PXDN,	RPL30,	RPSA,	S100A7,	S100A8,	S100A9,	SAA1,	SAA2,	TGFB1, THBS1,	TIMP1,	TMSB4X,	TNK2,	
TRIM25,	TRIM28,	TUBB,	UBE2N,	VCAM1,	VDAC1,	VNN1,	XRCC6
Leukocyte	
Activation
•ACTR2,	ADA,	AGA,	AGL,	ANXA2,	ANXA3,	APEH,	APP,	ARHGAP45,	ARPC5,	ATP11B,	B2M, CAND1,	CPNE1,	CTSA,	DSC1,	
ELANE,	FTH1,	FTL,	GPNMB,	GUSB,	HBB,	HLA-B,	HLA-DRA,	HMGB3,	HPRT1,	IGHA1,	IGHA2,	IGHG1,	IGHG2,	IGHG3,	
IGHG4,	IGHM,	IGKC,	IQGAP2,	JUP,	LAMTOR3,	LBP,	LDLR,	LRG1,	MANBA,	MAPK14,	MGAM,	MME,	MMP9,	NAPRT,	
NOTCH2,	ORM1,	PGAM1,	PGLYRP1,	PIGR,	PKM,	PNP,	PPBP,	PPIA,	PRCP,	PRDX6,	PRG2,	PRSS2,	PSMA2,	PSMA5,	
PSMB7,	PSMC3,	PSMD1,	PTPRJ,	PXDN,	PYGB,	PYGL,	RAB7A,	RPSA,	S100A11,	S100A7,	S100A8,	S100A9,	SERPINB3,	
STK10,	TCN1,	TFRC,	TGFB1, THBS1,	THY1,	TIMP1,	TUBB,	TXNDC5,	VCAM1,	VNN1,	XRCC6
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Statistically	significant,	overrepresented	proteins	were	determined	and	grouped	
into	biological	process	and	reactome	pathways,	illustrated	as	bar	charts,	Figure	19	
and	Figure	20	(P	<0.05)	(fold	change	>2.0).		
	
Figure	19,	illustrates	the	identified	enriched	proteins	which	are	found	to	be	
significantly	over	represented	in	biological	processes,	with	the	greatest	over-
representation	involved	in,	complement	activation	(P	<0.001,	fold	change	8.24),	B	
cell	mediated	immunity	(P	<0.001,	fold	change	8.24),	cell	recognition	(P		<0.001,	
fold	change	10.64),	defence	response	to	bacteria	(P	<0.001,	fold	change	6.92),	
glycolysis	(P	<0.001,	fold	change	10.64)	and	glycogen	metabolic	process	(P	<0.001,	
fold	change	6.81).	Over-	representation	of	other	biological	process	included	
response	to	biotic	stimulus	(P	<0.001,	fold	change	5.38),	fatty	acid	beta	oxidation	(P	
<0.001,	fold	change	5.96),	chromatin	remodelling	(P	<0.001,	fold	change	5.26),	
purine	nucleobase	metabolic	process	(P	<0.001,	fold	change	5.23),		immune	
response	(p	value	<0.001,	fold	change	3.42),	immune	system	process	(P	<0.05,	fold	
change	2.49,	protein	metabolic	processes	(P	<0.001,	fold	change	2.33),	endocytosis	
(P	<0.001,	fold	change	3.31),	proteolysis	(P	<0.001,	fold	change	2.53),	proteins	
folding	(P	<0.001,	fold	change	3.17)	and	angiogenesis	(P	<0.001,	fold	change	3.31)	.		
	
The	significantly	over-represented	proteins	were	mainly	found	to	be	in	biological	
processes	mainly	involved	with	the	immune	response	(immune	system	process,	B	
cell	mediated	immunity,	cell	recognition	and	defence	response	to	bacterium),	
inflammation	(complement	activation),	angiogenesis,	intra-cellular	protein	
transport	(endocytosis),	energy	metabolism	(glycolysis,	glycogen	metabolic	
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process,	fatty	acid	beta	oxidation)	and	protein	synthesis	and	breakdown	
(proteolysis,	protein	folding,	protein	metabolic	process	and	chromatin	remodelling)	
(Figure	19	and	Table	9).		
	
	
	
	
Figure	19:	Bar	Chart	of	over-representation	of	biological	processes	of	the	significantly	enriched	
proteins	when	compared	to	expected	values.	The	input	values	(blue)	and	expected	values	(orange)	
are	mapped	according	to	their	biological	process	on	the	abscissa	axis	(x)	and	number	of	proteins	
involved	on	the	ordinate	axis	(y).	PANTHER	(Version	11..0),	(P	<0.05,	fold	change	>2.0).		
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Figure	20,	illustrates	the	identified	enriched	proteins	which	are	significantly	over	
represented	in	reactome	pathways,	with	the	greatest	over-representation	involved	
in,	complement	cascade	(P	<0.001,	fold	change	8.86),	classical	antibody	mediated	
compliment	activation	(P	<0.001,	fold	change	15.69),	initial	triggering	of	
complement	(P	<0.001,	fold	change	12.61),	synthesis	of	prostaglandins	and	
thromboxane(P	<0.001,	fold	change	11.92),	down	regulation	of	TGFb1	receptor	
signalling	(P	<0.001,	fold	change	9.54)	and	TGFb	receptor	signalling	activates	
SMADs	(P	<0.001,	fold	change	7.69).	Over	representation	of	other	reactome	
pathways	include	the	Innate	immune	system	(P	<0.001,	fold	change	3.57),	VEGFA-
VEGFR2	pathway	(P		<0.001,	fold	change	4.09),		platelet	activation,	signalling	and	
aggregation	(P	<0.001,	fold	change	4.13),	platelet	degranulation	(P	<0.001,	fold	
change	6.68),	signalling	by	SCF-KIT	(P	<0.001,	fold	change	3.46),	class	I	MHC	
mediated	antigen	processing	and	presentation	(P	<0.001,	fold	change	2.42),	MHC	
class	II	antigen	presentation	(P	<0.001,	fold	change	3.54),	T	cell	receptor	signalling	
(P	<0.001,	fold	change	6.35).	
	
The	analysis	demonstrated	that	the	reactome	pathways	that	were	shown	to	be	
significantly		over-represented	mainly	involved	pathways	contributing	to	increased	
proliferation,	migration	survival	and	differentiation	of	hematopoietic	progenitors	
(Signalling	by	SCF-KIT),	complement	(creation	of	C4	&	C2	activators,	initial	
triggering	of	complement,	complement	cascade,	classical	antibody	mediated	
compliment	activation)	,	T-cell	proliferation,	differentiation	and	activation	(class	I	&	
II	MHC	mediated	antigen	processing	and	presentation,	T-cell	receptor	signalling),	
cell	proliferation,	migration	and	survival,	angiogenesis	and	tissue	repair	and	
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Inflammation	(VEGFA-VEGFR2	pathway	and	signalling	by	FGR2)	(Figure	20	and	
Table	10).	
	
	
Figure	20:	Bar	Chart	of	over-representation	of	Reactome	pathways	of	the	significantly	enriched	
proteins	when	compared	to	expected	values.	The	input	values	(blue)	and	expected	values	(orange)	
are	mapped	according	to	their	biological	process	on	the	abscissa	axis	(x)	and	number	of	proteins	
involved	on	the	ordinate	axis	(y).	PANTHER	(Version	11..0),	(P	<0.05,	fold	change	>2.0).		
	
Significant	over	representation	of	proteins	involved	in	these	highlighted	biological	
processes	and	reactome	pathways,	including	P	value	and	fold	change,	are	shown	in	
Tables	9	and	10.	The	input	column	is	the	number	of	the	significantly	upregulated	
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protein	that	are	grouped	based	on	the	PANTHER	classification	-	biological	process.	
The	PANTHER	reference	list	column	contains	the	number	of	proteins	involved	with	
the	biological	process.	The	expected	value	is	the	number	of	proteins	that	would	be	
expected	to	be	present	in	the	input	list	for	a	specific	biological	process	on	the	basis	
of	the	reference	list.	Therefore,	if	the	biological	process	under	investigation,	more	
proteins	are	observed	in	the	input	list	that	expected,	fold	change	>2.0,	there	is	an	
over	representation	(+)	of	the	proteins	involved	in	that	specific	biological	function.	
P	<0.05	determines	if	the	over-representation	is	significant	or	not.		
	
PANTHER	analysis	demonstrated	many	biological	processes	and	reactome	
pathways	shown	to	be	over	represented	are	central	to	pro-inflammation,	immune	
response,	increased	cell	survival	and	differentiation	in	the	pathophysiology	of	
systematic	mastocytosis.		
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Table	9:	Significant	over	representation	of	biological	processes	in	PANTHER.	Over-representation	
was	determined	by	number	of	proteins	in	PANTHER	reference	list	as	well	as	number	of	Inputted	
significantly	upregulated	proteins.	P	<0.05	and	fold	change	>2.0	was	considered	significantly	over-
represented.		
	
Biological	
Process	
PANTHER-
Ref	List	
	Input	 	Expected	 over/under	
representation	
Fold	
Enrichment	
P-value	
protein	metabolic	
process		
	
1583	 62	 26.56	 +	 2.33	 8.84E-10	
immune	system	
process		
	
669	 28	 11.22	 +	 2.49	 2.26E-05	
immune	response		 383	 22	 6.43	 +	 3.42	 1.18E-06	
endocytosis		 378	 21	 6.34	 +	 3.31	 3.40E-06	
proteolysis		 448	 19	 7.52	 +	 2.53	 3.05E-04	
complement	
activation		
	
94	 13	 1.58	 +	 8.24	 2.42E-08	
B	cell	mediated	
immunity		
	
94	 13	 1.58	 +	 8.24	 2.42E-08	
cell	recognition		 105	 13	 1.76	 +	 7.38	 7.89E-08	
defence	response	to	
bacterium		
	
112	 13	 1.88	 +	 6.92	 1.57E-07	
response	to	biotic	
stimulus		
	
144	 13	 2.42	 +	 5.38	 2.16E-06	
glycolysis		 28	 5	 0.47	 +	 10.64	 1.93E-04	
purine	nucleobase	
metabolic	process		
	
57	 5	 0.96	 +	 5.23	 3.56E-03	
protein	folding		 94	 5	 1.58	 +	 3.17	 2.41E-02	
glycogen	metabolic	
process		
	
35	 4	 0.59	 +	 6.81	 3.80E-03	
chromatin	
remodelling		
	
34	 3	 0.57	 +	 5.26	 2.29E-02	
fatty	acid	beta-
oxidation		
	
20	 2	 0.34	 +	 5.96	 5.05E-02	
angiogenesis		 18	 1	 0.3	 +	 3.31	 2.71E-01	
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Table	10:	Significant	over	representation	of	Reactome	pathways	in	PANTHER.	Over-representation	
was	determined	by	number	of	proteins	in	PANTHER	reference	list	as	well	as	number	of	Inputted	
significantly	upregulated	proteins.	P	<0.05	and	fold	change	>2.0	was	considered	significantly	over-
represented.		
	
	
Reactome	pathways	 PANTHER-
Ref	List	
Input		 Expected	 Over/under	
representation	
Fold	
Enrichment	
	P-value	
Innate	Immune	System		
	
38	 47	 13.15	 +	 3.57	 1.57E-13	
VEGFA-VEGFR2	Pathway		
	
43	 21	 5.13	 +	 4.09	 1.35E-07	
Signaling	by	FGFR2		
	
52	 20	 5.8	 +	 3.45	 3.32E-06	
Platelet	activation,	signaling	
and	aggregation		
	
15	 19	 4.6	 +	 4.13	 4.65E-07	
Signaling	by	SCF-KIT		
	
25	 18	 5.2	 +	 3.46	 9.70E-06	
Class	I	MHC	mediated	antigen	
processing	&	presentation		
	
19	 15	 6.19	 +	 2.42	 1.91E-03	
Platelet	degranulation			
	
74	 14	 2.1	 +	 6.68	 7.81E-08	
TCR	signaling		
	
31	 13	 2.05	 +	 6.35	 3.86E-07	
Creation	of	C4	and	C2	
activators		
	
125	 11	 0.72	 +	 15.25	 1.07E-09	
Initial	triggering	of	
complement		
	
122	 11	 0.87	 +	 12.61	 6.04E-09	
Complement	cascade		
	
274	 11	 1.24	 +	 8.86	 1.52E-07	
Classical	antibody-mediated	
complement	activation		
	
306	 10	 0.64	 +	 15.69	 4.93E-09	
MHC	class	II	antigen	
presentation		
	
784	 7	 1.98	 +	 3.54	 4.75E-03	
Downregulation	of	TGF-beta	
receptor	signaling		
	
118	 4	 0.42	 +	 9.54	 1.25E-03	
TGF-beta	receptor	signaling	
activates	SMADs		
	
310	 4	 0.52	 +	 7.69	 2.55E-03	
Synthesis	of	Prostaglandins	
(PG)	and	Thromboxanes	(TX)		
	
346	 3	 0.25	 +	 11.92	 3.02E-03	
Regulation	of	TLR	by	
endogenous	ligand		
369	 3	 0.32	 +	 9.41	 5.43E-03	
	
	
	
	
	
	
	 86	
3.8	SWATH	Ion	intensity	Graph	and	ELISA	
	
To	quantify	proteins	between	patients	and	controls,	SWATH-MS	ion	intensity	
graphs	were	plotted	for	key	proteins	that	belong	to	immune	response	(Table	8)	
shown	in	Figure	21,	22,	23	and	24.		
	
SWATH	Data	indicated	that	CRP	was	significantly	up	regulated	in	patients	when	
compared	to	healthy	control	group	as	shown	below	in	figure	21	(Fold	Change	3.62	
patients	vs	controls,	P	<0.001).			
	
Figure	21:	Box	and	whisker	plot	showing	C-Reactive	Protein	(CRP)	intensity	of	the	peptide	ions	of	
SWATH-MS	between	patients	and	control	groups	(Mean	and	SD).	Peptide	ion	intensity	are	plotted	
on	the	abscissa	axis	(x)	and	participant	and	control	group	on	the	ordinate	axis	(y)	A	P	<	0.001.		
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SWATH	Data	indicated	that	TGFb1	was	significantly	up	regulated	in	patients	when	
compared	to	healthy	control	group	as	shown	below	in	figure	22	(Fold	change	2.06	
patients	vs	controls,	P<0.001).			
	
	
Figure	22:	Box	and	whisker	plot	showing	Transforming	growth	factor	beta	1	(TGFb1)	intensity	of	
the	peptide	ions	of	SWATH-MS	between	patients	and	control	groups	(Mean	and	SD).	Peptide	ion	
intensity	are	plotted	on	the	abscissa	axis	(x)	and	participant	and	control	group	on	the	ordinate	axis	
(y).	P	<0.001	
	
SWATH	Data	indicated	that	platelet	basic	protein	(CXCL7)	was	significantly	up	
regulated	in	patients	when	compared	to	heathy	control	group	as	shown	below	in	
figure	23	(Fold	change	4.83	patients	vs	controls,	P<0.001).			
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Figure	23:	Box	and	whisker	plot	showing	Platelet	basic	protein	(CXCL7)	intensity	of	the	peptide	
ions	of	SWATH-MS	between	patients	and	control	groups	(Mean	and	SD).	Peptide	ion	intensity	are	
plotted	on	the	abscissa	axis	(x)	and	participant	and	control	group	on	the	ordinate	axis	(y).	P	<0.001)	
	
SWATH	Data	indicated	that	beta	2	microglobulin	(b2M)	was	significantly	up	
regulated	in	patients	when	compared	to	heathy	control	group	as	shown	below	in	
figure	24	(Fold	change	1.9	patients	vs	controls,	P<0.001).			
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Figure	24:	Box	and	whisker	plot	showing	beta	2	microglobulin	(b2M)	intensity	of	the	peptide	ions	
of	SWATH-MS	between	patients	and	control	groups	(Mean	and	SD).	Peptide	ion	intensity	are	
plotted	on	the	abscissa	axis	(x)	and	participant	and	control	group	on	the	ordinate	axis	(y).	A	P	
<0.001)	
	
Orthogonal	confirmation	of	the	SWATH-MS	data	was	preformed	using	
commercially	available	ELISA’s	in	order	to	confirm	the	changes	seen	in	the	plasma	
proteome.	C-reactive	protein,	beta	2	microglobulin,	transforming	growth	factor	
beta	1,	platelet	basic	protein,	liposaccharide	binding	protein,	and	platelet	derived	
growth	factor	receptor	were	measured,	by	commercially	available	ELISA,	in	the	
plasma	of	7	patients	and	7	controls.		
Each	of	the	plasma	protein	measurements	were	compared	between	patients	and	
healthy	control	group,	using	independent	t-tests,	with	statistical	differences	
illustrated	in	figures	25,26,27,28,29	and	30,	and	values	reported	in	table	11.	A	
P<0.05	was	considered	statistically	significant.		
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Figure	25	and	Table	11	shows,	patients	with	SM	had	a	significantly	increased	mean	
circulating	plasma	concentration	of	CRP,	compared	to	controls	(417.6	pg/ml	vs	
76.14	pg/ml,	P	=	0.02)	
	
	
Figure	25:		Box	and	Whiskers	plot	showing	circulating	levels	of	C-Reactive	protein	(CRP)	(pg/ml)	in	
patients	with	systematic	mastocytosis	and	apparently	heathy	controls	(Mean	and	SD).	Plasma	
protein	measurements	were	compared	between	systemic	mastocytosis	patients	(Green)	and	
healthy	controls	(Red)	using	Independent	t-tests.	P	=	0.02.	A	P<0.05	was	considered	Statistically	
significant.	(*<0.05,	**<0.01,***<0.001).		
	
	
Figure	26	and	Table	11	shows,	patients	with	SM	had	a	significantly	increased	mean	
circulating	plasma	concentration	of	Platelet	Derived	Growth	Factor	Receptor	Beta,	
compared	to	controls	(538.8	pg/ml	vs	293.3	pg/ml,	P	=	0.006)	
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Figure	26:		Box	and	Whiskers	plot	showing	circulating	levels	of	Platelet	Derived	Growth	Factor	
Beta	(PDGFrb)	(pg/ml)	in	patients	with	systematic	mastocytosis	and	apparently	heathy	controls	
(Mean	and	SD).	Plasma	protein	measurements	were	compared	between	systemic	mastocytosis	
patients	(Green)	and	healthy	controls	(Red)	using	Independent	t-tests.	P	=	0.006.	A	P<0.05	was	
considered	Statistically	significant.	(*<0.05,	**<0.01,***<0.001).		
	
Figure	27	and	Table	11	shows,	patients	with	SM	had	a	significantly	increased	mean	
circulating	plasma	concentration	of	Platelet	Basic	Protein,	compared	to	controls	
(167.2	pg/ml	vs	59.78	pg/ml,	P	=	0.04)	
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Figure	27:		Box	and	Whiskers	plot	showing	circulating	levels	of	Platelet	Basic	Protein	(CXCL7)	
(pg/ml)	in	patients	with	systematic	mastocytosis	and	apparently	heathy	controls	(Mean	and	SD).	
Plasma	protein	measurements	were	compared	between	systemic	mastocytosis	patients	(Green)	and	
healthy	controls	(Red)	using	Independent	t-tests.	P	=	0.04.	A	P<0.05	was	considered	Statistically	
significant.	(*<0.05,	**<0.01,***<0.001).		
	
Figure	28	and	Table	11	shows,	patients	with	SM	had	a	significantly	increased	mean	
circulating	plasma	concentration	of	liposaccharide	binding	protein,	compared	to	
controls	(93.54	ng/ml	vs	80.67	ng/ml,	P	=	0.02)	
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Figure	28:		Box	and	Whiskers	plot	showing	circulating	levels	of	Liposaccharide	binding	protein	
(LBP)	(ng/ml)	in	patients	with	systematic	mastocytosis	and	apparently	heathy	controls	(Mean	and	
SD).	Plasma	protein	measurements	were	compared	between	systemic	mastocytosis	patients	
(Green)	and	healthy	controls	(Red)	using	Independent	t-tests.	P=	0.02.	A	P<0.05	was	considered	
Statistically	significant.	(*<0.05,	**<0.01,***<0.001).		
	
Figure	29	and	Table	11	shows,	patients	with	SM	had	a	significantly	increased	mean	
circulating	plasma	concentration	of	Transforming	Growth	Factor	Beta	1,	compared	
to	controls	(1823	pg/ml	vs	748.7	pg/ml,	P	=	0.02)	
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Figure	29:		Box	and	Whiskers	plot	showing	circulating	levels	of	Transforming	Growth	Factor	Beta	1	
(TGFb1)	(pg/ml)	in	patients	with	systematic	mastocytosis	and	apparently	heathy	controls	(Mean	
and	SD).	Plasma	protein	measurements	were	compared	between	systemic	mastocytosis	patients	
(Green)	and	healthy	controls	(Red)	using	Independent	t-tests.	P=	0.02.	A	P<0.05	was	considered	
Statistically	significant.	(*<0.05,	**<0.01,***<0.001).		
	
	
	
Figure	30	and	Table	11	shows,	patients	with	SM	had	non-statistically	significant	
increased	mean	circulating	plasma	concentration	of	Beta	2	Microglobulin,	
compared	to	controls	(437.8	pg/ml	vs	180.2	pg/ml,	P	=	0.21)	
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Figure	30:		Box	and	Whiskers	plot	showing	circulating	levels	of	Beta	2	microglobulin	(b2M)	(pg/ml)	
in	patients	with	systematic	mastocytosis	and	apparently	heathy	controls	(Mean	and	SD).	Plasma	
protein	measurements	were	compared	between	systemic	mastocytosis	patients	(Green)	and	
healthy	controls	(Red)	using	Independent	t-tests.	P=	0.21.	A	P<0.05	was	considered	Statistically	
significant.	(*<0.05,	**<0.01,***<0.001).		
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Table	11:	Circulating	plasma	levels	of	C-Reactive	Protein	(CRP),	Beta	2	Microglobulin	(b2M),	
Transforming	Growth	Factor,	Beta	1	(TGFb1),	Platelet	Basic	Protein	(PPBP/CXCL7),	Liposaccharide	
Binding	Protein	(LBP)	and	Platelet	Derived	Growth	Factor	Receptor	(PDGFR).	Plasma	protein	
measurements	were	compared	between	systemic	mastocytosis	patients	and	healthy	controls	using	
Independent	t-tests.	A	P<0.05	was	considered	statistically	significant	(*P	<0.05,	**<0.01,	
***<0.001).				
	
	
	 Total	 Mastocytosis	
Patients		
Control	
C-Reactive	protein	(pg/ml)	
	
246.87	
(225.12)	
	
	417.6	(375.5)	
*	
76.14	(74.73)	
Beta	2	Microglobulin	(pg/ml)	
	
309	(310.21)	 437.8	(597.8)	 180.2	(22.62)	
Transforming	Growth	Factor,	
Beta	1	(pg/ml)	
	
1286	(598.8)	 1823	(982.6)*	 748.7	(214.9)	
Platelet	Basic	Protein		
(pg/ml)	
	
113.49	(80.85)	 167.2	(122.5)	*	 59.78	(39.2)		
Liposaccharide	Binding	
Protein	(ng/ml)		
	
87.105	(9.39)	 93.54	(9.103)*	 80.67	(9.682)	
Platelet	Derived	Growth	
Factor	Receptor	(PDGFR)	
(pg/ml)	
	
416.05	
(137.35)	
538.8	
(149.4)**	
293.3	(125.3)	
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Chapter	4:	Discussion		
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4.1	Identification	of	Proteins		
	
Screening	for	novel	protein	biomarkers	from	human	plasma	can	provide	essential	
clinical	information.	In	the	current	project,	SWATH-MS	was	used	to	identify	
proteins	in	patients	with	SM,	compared	to	healthy	controls	and	to	assess	any	
difference	in	concentration.	A	total	of	1437	proteins	were	identified	at	a	1%	FDR	
and	99%	peptide	confidence.	The	identification	of	1437	proteins	in	the	plasma	
samples	of	patients	with	SM	is	comparable	to	other	reports	in	the	literature.	
Recently,	Miyauchi	and	colleagues	(2018)	report	the	identification	of	blood	
biomarkers	in	Glioblastoma	using	SWATH-MS.	In	this	study,	the	authors	reported	
the	identification	of	962	proteins	with	a	1%	FDR	and	99%	protein	confidence	in	
samples	derived	from	14	patients	(Miyauchi	et	al.,	2018).	In	addition,	a	
comparative	proteomic	analysis	of	five	body	fluids	(plasma,	urine,	cerebrospinal	
fluid,	amniotic	fluid	and	saliva)	reported	the	identification	of	1189	proteins	in	
plasma	samples	derived	from	25	apparently	healthy	participants	with	a	1%	FDR	and	
99%	protein	confidence	(Zhao	et	al.,	2018).	It	is	worthy	of	note	however,	that	
Miyauchi	and	colleagues	(2018)	did	not	immunodeplete	the	high	abundance	
proteins	during	pre-analytical	sample	preparation.		
While	SWATH-MS	is	not	the	only	technique	that	could	have	been	utilised	for	the	
identification	of	proteins	it	has	a	number	of	advantages	when	compared	to	the	
others.	The	run	time	for	SWATH-MS	is	significantly	less	than	other	techniques.	In	
their	2018	paper,	Johnston	(2018)	and	colleagues	report	a	LC-MS/MS	technique	for	
proteomic	profiling	of	CLL.	The	run	time	reported	in	that	study	was	210hours,	
compared	to	2	hours	for	SWATH-MS.	In	addition,	to	a	decrease	in	analytical	run	
time,	SWATH-MS	has	demonstrated	enhanced	sensitivity,	reliability	and	precision	
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with	lower	sample	volumes	than	isobaric	tags	for	relative	and	absolute	
quantification	(iTRAQ)-MS	making	it	a	superior	technique	for	biomarker	discovery	
in	clinical	samples	(Jylha	et	al,	2018).		
	
4.2	Summary	of	Results		
	
The	results	of	the	current	SWATH-MS	study	in	patients	with	systematic	
mastocytosis	have	demonstrated	the	enrichment	of	360	proteins	involved	in	
immune	system	process,	innate	immune	response,	response	to	stimulus,	defence	
response	and	leucocyte	activation.	Further	analysis	has	also	demonstrated	
statistical	over-representation	of	proteins	involved	in	biological	process	and	
reactome	pathways,	supporting	the	results	above.	Formal	immunoassay	
quantification	by	ELISA	of	proteins	identified	as	common	to	all	the	above	pathways	
has	shown	significantly	increased	levels	of	CRP,	CXCL7,	LBP,	TGFb1	and	PDGF	
receptor-b	in	patients	with	systemic	mastocytosis	when	compared	to	an	apparently	
healthy	control	population.	Levels	of	B2M	were	also	increased	in	patients	when	
compared	to	controls,	however	the	difference	did	not	reach	statistical	significance,	
most	likely	due	to	the	large	spread	of	results.		
	
4.3	Sample	Preparation		
	
Sample	preparation	is	considered	an	integral	part	of	pre-analytical	sample	
preparation	and	can	significantly	influence	the	overall	analytical	sensitivity	of	
SWATH-MS.	Due	to	the	complexity	of	the	plasma	sample	matrix	and	depth	of	
proteome,	a	range	of	sample	preparation	strategies	have	been	developed	for	
targeted	protein	quantification.	One	of	the	most	effective	and	most	commonly	
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used	techniques	is	the	depletion	of	highly	abundant	proteins	to	enhance	the	
analytical	dynamic	range	and	detection	sensitivity.	For	the	analysis	of	plasma	
samples,	the	depletion	and	tryptic	digestion	processes,	as	reported	in	Chapter	2,	
are	therefore	critically	important	in	sampling	processing,	impacting	the	accuracy	
and	precision	of	protein	quantification	overall	(Pan,	et	al	2009).	
	
In	accordance	with	manufactures	instructions	(Pierce,	Thermos	Scientific,	Rockford,	
USA),	the	top	twelve	most	highly	abundant	proteins	(>95%)	(Table	12)	were	
removed	from	10	µl	of	peripheral	blood	plasma	using	depletion	spin	columns	
containing	a	resin	of	immobilised	highly	specific	antibodies,	whilst	providing	
minimal	nonspecific	interactions	with	other	proteins.	Removing	>95%	of	these	top	
12	abundant	proteins	from	the	plasma	samples	enabled	the	identification	and	
quantification	of	low	abundance	proteins	by	mass	spectrometry,	removing	the	
interference	from	the	most	abundant	tryptic	peptides	which	may	mask	the	
identification	of	the	less	abundant	peptides.	Previous	reports	have	shown	that	the	
less	abundant	peptides	are	often	derived	from	proteins	of	biological	importance	
(Dayon,	2013).	
	
	
4.4	SWATH-MS,	Data	Independent	Analysis		
	
MS	can	be	either	data	dependent	acquisition	(DDA)	or	data	independent	acquisition	
(DIA).	In	DDA,	a	set	of	fixed	rules	and	parameters	must	be	set	in	advance.	Peptides	
are	ionised	and	analysed,	and	a	fixed	number	of	predefined	peptides	are	selected	at	
random	for	fragmentation.	This	produces	a	tandem	MS/MS	mass	spectra	that	can	
be	matched	to	spectra	in	an	existing	database.	Although	the	selection	is	random,	the	
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most	 abundant	 peptides	 are	 the	 ones	 selected	 based	 on	 having	 a	 much	 higher	
concentration	 in	 the	 sample,	meaning	 it	 is	 difficult	 to	 reproducibly	 quantify	 and	
identify	the	lowest	abundance	peptides	in	the	sample	(Kang	et	al	2017).		
In	 contrast,	 when	 utilising	 DIA	 all	 the	 peptides	 identified	 are	 subjected	 to	
fragmentation	 without	 being	 predefined	 enabling	 improved	 accuracy	 in	 peptide	
quantification	and	profiling.	
SWATH	MS	 is	 a	 DIA	 approach	 enabling	 a	 highly	 comprehensive	 interpretation	 of	
proteins	and	peptides	in	complex	samples	(Kang	et	al	2017).	SWATH	permits,	 in	a	
single	step,	the	identification	and	quantification	of	peptides	eradicating	the	need	for	
multiple	scans.	Consequently,	SWATH	has	an	improved	turnaround	time,	accuracy	
and	 reduced	 error	 rate	 when	 compared	 with	 DDA.	 Only	 the	 DIA	 approach	
comprehensively	 detects	 and	 analyses	 every	 detectable	 compound	 within	 the	
sample	under	investigation	(Kang	et	al	2017).	
	
4.5	Enriched	Protein	Biological	Process	and	Pathway	Involvement		
	
	
Clugo	and	DAVID	databases	were	used	to	explore	the	role	of	the	significantly	
enriched	proteins	identified	by	SWATH-MS	in	biological	processes	and	KEGG	
pathways.	Analysis	revealed	that	proteins,	identified	in	this	study,	are	largely	
involved	in	metabolic	process,	immune	response,	regulation	of	development	and	
cell	adhesion,	migration	and	cell	surface	receptor	signalling	pathways.	Based	on	
biological	functional	analysis,	identified	proteins	largely	play	roles	in	the	immune	
response.	In	addition,	according	to	the	KEGG	pathway	annotation,	identified	
proteins	involved	within	the	immune	response,	were	classified	into	different	
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pathways	including	immune	system	process,	the	innate	immune	response,	
response	to	stimulus,	defence	response	and	leukocytes	activation.	Further	analysis,	
using	PANTHER	supported	the	above	findings	and	identified	that	enriched	proteins	
were	significantly	over	represented	in	biological	processes	such	as,	immune	
response	immune	system	process,	compliment	activation,	B	cell	mediated	
immunity,	glycolysis	and	cell	recognition.		
	
In	addition,	PANTHER	identified	enriched	proteins	found	to	be	significantly	over	
represented	in	Reactome	pathways	such	as	the	Innate	immune	system,	VEGFA-
VEGFR2	pathway,	platelet	activation,	signalling,	aggregation	and	degranulation.	
Signalling	by	SCF-KIT,	Class	I	MHC	mediated	antigen	processing	and	presentation,	
MHC	class	II	antigen	presentation,	T	cell	receptor	signalling,	compliment	cascade,	
classical	antibody	mediated	compliment	activation,	initial	triggering	of	compliment,	
down	regulation	of	TGFB1	receptor	signalling	and	TGF-beta	receptor	signalling	
pathways	were	also	identified.		
	
The	results	of	the	current	bioinformatics	analysis	identified	up	regulated	proteins	
derived	from	immunoglobulins,	acute	phase	reactants	and	binding	proteins	
thought	to	play	crucial	roles	in	immune	system	regulation,	inflammation	and	acute	
inflammatory	response.		These	pathways	are	highly	relevant	to	the	present	study	
since	systemic	mastocytosis	is	a	disease	caused	by	abnormalities	which	affect	the	
immune	system.	To	further	support	the	results	obtained	from	the	SWATH-MS	
analysis,	circulating	plasma	levels	of	C-reactive	protein	(CRP),	Beta	2	Microglobulin	
(B2M),	Transforming	Growth	Factor-b1	(TGFb1),	Liposaccharide	Binding	Protein	
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(LBP),	Platelet	Binding	Protein	(CXCL7/PBP)	and	Platelet	Derived	Growth	Factor	
Receptor-b	(PDGFRb),	were	quantified	by	ELISA.			
	
4.6	C-	Reactive	Protein		
	
The	results	of	the	current	investigation	have	demonstrated	a	significantly	increased	
circulating	plasma	level	of	CRP	in	patients	with	systemic	mastocytosis	using	both	
SWATH-MS	and	ELISA	techniques.		
CRP	is	predominantly	synthesised	by	the	liver,	as	a	part	of	the	acute-phase	
response,	(Hurlimann	et	al.,	1966).	Extra-hepatic	synthesis	of	CRP	has	also	been	
reported	in	organs	such	as	the	kidneys	suggesting	local	synthesis	of	CRP	(Becker,	et	
al.,	1980	&	Nakahara,	et	al.,	2001).	Irrespective	of	the	site	of	synthesis,	CRP	is	
deposited	at	sites	of	acute	inflammation	(Du	Clos	&	Mold.,	2004).	The	main	stimuli	
to	CRP	synthesis	include	interleukin	(IL)-6	and	IL-1	however,	several	different	
agents,	such	as	corticosteroids,	can	alter	synthesis	of	CRP.	CRP	is	a	classical	acute	
phase	protein	with	its	blood	concentration	increasing	from	<	1µg/mL	to	as	high	as	
600-1000µg/mL	during	at	the	maxima	of	an	acute	phase	response	(Du	Clos	&	
Mold.,	2004).	In	myocardial	infarction,	levels	may	rise	from	<	2µg/mL	to	over	
100µg/mL	in	approximately	24	hours	(Kushner,	et	al.,	1978).	In	addition,	levels	
>500µg/mL	have	been	reported	in	patients	with	sepsis	following	burn	injury.		
CRP	levels,	in	general,	reflect	circulating	IL-6	levels	and	correlate	with	inflammation	
and	other	makers	of	the	acute	phase	response,	such	as	erythrocyte	sedimentation	
rate.	CRP	levels,	however	Increase	and	decrease	more	rapidly	than	many	other	
acute	phase	proteins,	therefore	making	it	a	useful	marker	to	follow	clinical	disease	
course	and	response	to	treatment	(Du	Clos	&	Mold.,	2004).	Despite	a	
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comprehensive	literature	search,	the	author	was	unable	to	identify	any	clinical	
studies	of	the	role	of	CRP	in	systematic	mastocytosis.	In	multiple	myeloma,	
however	Devetzoglou	and	colleagues	(2015),	reported	a	correlation	between	mast	
cell	density	and	IL-6	and	CRP	in	86	patients	of	varying	degrees	of	disease	severity.	
In	this	study,	it	was	also	reported	an	increase	in	mortality	in	patients	with	increased	
mast	cell	density,	although	the	investigators	evaluate	this	with	IL-6	or	CRP.	It	
should	be	noted	however	that	the	number	of	patients	was	small	and	there	was	
quite	a	spread	of	results	for	mast	cell	density,	IL-6	and	CRP	on	visual	inspection	of	
the	data.	Further	a	more	recent	study	by	Herishanu	and	colleagues	(2017)	reported	
that	increased	circulating	CRP	concentrations	are	associated	with	increased	
mortality	and	the	development	of	future	solid	tumours	in	patients	with	chronic	
lymphocytic	leukaemia.	Again,	however	the	number	of	patients	was	small	(n=107).	
The	exact	role	of	CRP	in	the	current	study	and	studies	reported	above	remains	to	
be	elucidated,	however	earlier	work	by	Fujimoto	and	colleagues	(2003)	has	shown	
that	CRP	can	activate	mast	cells	in	a	canine	model.			
	
4.7	Transforming	Growth	Factor	Beta	1	
	
The	results	of	the	current	investigation	have	demonstrated	a	significantly	increased	
circulating	plasma	level	of	TGFb1	in	patients	with	systemic	mastocytosis	using	both	
SWATH-MS	and	ELISA	techniques.		
	
Transforming	growth	factor	beta	is	a	multipotent	cytokine	comprising	of	TGFb1,2	
and	3	(Derynck	&	Zhang.,	2003).		TGFb1	is	the	most	abundant	isoform	in	most	
tissues,	including	the	skin,	and	is	secreted	in	a	biologically	latent	form	before	
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becoming	activated	when	mature	TGFb1	dissociates	from	its	latency	associated	
peptide	dimer	(Han	et	al.,	2012).	TGFb1	stimulates	migration	of	monocytes,	
lymphocytes,	neutrophils	and	fibroblasts	at	low	concentrations	(McCartney	&	
Wahl,	1994).		
	
Physiologically,	TGFb	signalling	is	essential	for	the	normal	regulation	of	cellular	
processes,	including	cell	survival,	migration,	proliferation	and	differentiation.	TGFb	
has	a	negative	impact	on	cellular	proliferation	while	stimulating	differentiation,	
mast	cell	activation	and	apoptosis	in	a	concentration	dependant	manner	during	
haematopoiesis	and	suggesting	an	important	role	during	tumorigenesis	(Dong	&	
Blobe,	2006,	Shi	&	Massague,	2003	and	Ndaw,	et	al.,	2017).		Further,	in	
haematological	malignancy,	the	normal	physiology	of	TGFb	can	be	modified	by	
oncoproteins,	suggesting	that	TGFb	may	have	a	tumour	suppressor	function	under	
normal	physiology	(Dong	&	Blobe,	2006).		
Clinically,	in	patients	with	hairy	cell	leukaemia,	Shehata	and	colleagues	(2004)	
reported	elevated	circulating	levels	of	TGFb1	and	confirmed	that	hairy	cells	were	
the	predominant	source	of	the	elevated	levels	(Dong	&	Blode,	2006).	Further	the	
authors	reported	that	TGFb1	was	also	present,	at	increased	concentration	in	bone	
marrow	derived	mononuclear	cells	(Shehata,	et	al.,	2004).	Moreover,	the	authors	
went	on	to	demonstrate	a	correlation	between	the	circulating	levels	of	TGFb1	and	
the	extent	of	bone	marrow	fibrosis.	(Shehata,	et	al.,	2004).	In	patients	with	
mastocytosis,	bone	marrow	reticulin	fibrosis	is	commonly	observed	(Li	&	Baek,	
2002).	Mast	cells	are	a	recognised	source	of	pro-fibrotic	cytokines,	including	TGFb1.	
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In	clinical	studies,	Li	and	colleagues	(2002)	have	reported	a	correlation	between	the	
circulating	plasma	levels	of	TGFb1	and	bone	marrow	fibrosis.	
	
4.8	Platelet	derived	Growth	Factor	Receptor	Beta			
	
The	results	of	the	current	investigation	have	demonstrated	a	significantly	increased	
circulating	plasma	level	of	PDGF	Receptor-beta	(PDGFrb)	in	patients	with	systemic	
mastocytosis	using	both	SWATH-MS	and	ELISA	techniques.		
	
Platelet	derived	growth	factor	is	a	potent	mitogenic	agent	for	fibroblasts	and	
smooth	muscle	cells,	and	exerts	its	effect	through	the	cell	surface	tyrosine	kinase	
domain	receptor	designated	the	PDGF	receptor	(Raica	&	Cimpean,	2010).	In	
addition,	mast	cells	have	been	shown	to	be	a	source	of	PDGF	(Li	&	Baek,	2002).	In	a	
recent	study,	Yang	and	colleagues	(2018)	reported	increased	expression,	by	
immunohistochemistry,	of	PGDFRb	on	leukemic	large	granular	lymphocytes.	In	
addition,	the	results	demonstrated	that	those	cells	expressing	PDGFRb	had	a	
significant	survival	advantage.	Similar	results	were	also	observed	when	PDGF	was	
assayed	directly	by	ELISA	in	the	serum	of	patients	with	large	granular	lymphocyte	
leukaemia.	The	results	from	Yang	and	colleagues	(2018)	also	support	the	earlier	
findings	of	Ulvestad	and	colleagues	(2001)	who	reported	PDGFRb	expression	in	
patients	with	human	acute	myelongenous	leukaemia.		
The	significance	of	PDGFRb	in	patients	with	mastocytosis	remains	to	be	elucidated	
with	no	reports	in	the	literature.	The	results	of	the	current	study	however	would	
suggest	that	PDGFRb	may	have	significance	in	this	group	of	patients.		
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4.9	Platelet	Basic	Protein	
	
The	results	of	the	current	investigation	have	demonstrated	a	significantly	increased	
circulating	plasma	level	of	platelet	basic	protein	(CXCL7)	in	patients	with	systemic	
mastocytosis	using	both	SWATH-MS	and	ELISA	techniques.		
	
In	their	recent	review,	Ntelis	and	colleagues	(2017)	discuss	the	potential	
significance	of	platelet	derived	growth	factors	in	many	autoimmune	and	vascular	
diseases,	including	a	role	in	the	development	of	fibrosis	and	is	released	following	
platelet	activation	(Ntelis,	et	al.,	2017	&	Li	&	Baek,	2002).	The	significance	of	
platelet	basic	protein	in	the	diagnosis	and	monitoring	of	mastocytosis	remains	to	
be	elucidated.		
	
4.10	Beta	2	Microglobulin		
	
The	results	of	the	current	investigation	have	demonstrated	a	significantly	increased	
circulating	plasma	level	of	b2M	in	patients	with	systemic	mastocytosis	using	
SWATH-MS	only.	Results	obtained	using	a	specific	ELISA	showed	increased	
circulating	plasma	levels	of	b2M	although	this	did	not	reach	statistical	significance.		
	
Beta	2	Microglobulin	(b2M)	is	a	non-glycosylated	polypeptide	of	100	amino	acid	
residues.	It	is	the	invariant	chain	of	the	major	histocompatibility	(MHC)	class	1	
molecules	on	the	cell	surface	of	nearly	all	nucleated	cells	and	is	present	in	most	
biological	fluids,	including	serum,	urine	and	synovial	fluid	(Drueke.,	2009),	and	
functions	to	stabilise	the	tertiary	structure	of	the	MCH	class	1	a-chain.	Free	b2M	
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can	be	measured	in	body	fluids	under	physiological	conditions	as	a	result	of	
shedding	from	cell	surfaces	or	intracellular	release.	b2M	is	mainly	catabolised	
within	the	kidney,	with	95%-100%	of	circulating	b2M	being	eliminated	through	
glomerular	filtration	(Karlsson,	et	al.,	1980).	In	renal	tubulopathies	quantities	of	
b2M	in	urine	are	increased,	reflecting	the	degree	of	renal	impairment.	If	the	rate	of	
glomerular	filtration	is	reduced,	the	level	of	serum	b2M	is	increased	therefore,	
serum	and	urine	concentrations	of	b2M	are	used	to	monitor	glomerular	and	
tubular	nephropathies	(Wilbell,	et	al.,	1978).	In	health,	the	serum	concentration	of	
b2M,	is	normally	<2mg/L	and	the	urinary	excretion	being	<	400µg/24	hours	(Xie,	et	
al.,	2003).	In	addition,	b2M	is	extensively	involved	in	the	functional	regulation	of	
cell	survival,	proliferation,	apoptosis	and	metastasis	in	cancer	cells	(Li,	et	al.,	2016).		
Other	groups	have	reported	that	increased	serum	b2M	levels	are	a	predictor	of	
poor	survival	in	several	haematological	malignancies	including	multiple	myeloma,	
Hodgkin	lymphoma,	acute	lymphoblastic	leukaemia,	chronic	myeloid	leukaemia,	
chronic	lymphocytic	leukaemia	and	myelodysplastic	syndromes	(Durie	et	al.,	1990,	
Chronowski	et	al.,2002,	Kantarjian	et	al.,	1992,	Molica	et	al.,	1999	and	Gatto	et	al.,	
2003).			
	
Further,	Durie	and	collugues	(1990)	described	serum	b2M	measurements	as	having	
the	highest	prognostic	significance	in	612,	previously	untreated	patients	with	acute	
multiple	myeloma,	then	any	other	prognostic	factor	measured.	Mean	survival	for	
patients,	with	pre-treatment	serum	b2M	values	of	<6µg/ml,	was	reported,	using	
radioimmunoassay,	as	36	months,	compared	with	a	mean	survival	rate	of	23	
months	for	225	patients	with	serum	b2M	³	6µg	/ml.	Serum	b2M	was	highly	
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correlated	with	stage	and	it	was	possible	to	stratify	myeloma	patient	into	low,	
intermediate	and	high	risk	categories	based	on	serum	b2M	levels	,	albumin	and	age	
(Durie	et	al.,	1990).		The	authors	concluded	that	serum	b2M	is	the	most	powerful	
prognostic	factor	currently	available	for	multiple	myeloma	and	that	it	can	be	used	
for	pre-treatment	stratification	(Durie	et	al.,	1990).	
Further	in	their	study	of	86	patients	with	multiple	myeloma,	Devetzoglou	and	
colleagues	(2015)	reported	a	correlation	between	mast	cell	density	and	b2M,	
although	the	data	was	widely	dispersed	on	visual	inspection.	As	previously	
reported	increased	mast	cell	density	was	associated	with	increased	mortality,	
although	a	formal	evaluation	of	b2M	as	a	predictor	of	outcome	was	not	included	in	
their	analysis.		
The	above	results	are	also	supported	by	results	of	earlier	studies	in	haematological	
malignancies,	which	reported	a	correlation	between	levels	of	b2M	and	outcome	
including	all-cause	mortality	(Campos.,	et	al.,	1984	&	Bataille	et	al.,	1984).		
	
4.11	Mastocytosis	and	Inflammation	
		
As	outlined	in	Chapter	1,	the	mast	cell	plays	a	significant	role	in	inflammation,	
secreting	a	number	of	biological	mediators.	The	increases	circulating	plasma	levels	
of	CRP,	Platelet	Derived	Growth	Factor	Receptor-b,	Platelet	Basic	Protein,	
Liposaccharide	Binding	Proteins,	Transforming	Growth	Factor-b1	and	Beta-2	
microglobulin	all	point	to	a	low	grade	inflammatory	state	in	patients	with	SM.	The	
increased	levels	of	CRP,	a	routinely	measured	marker	of	inflammation,	while	not	
clinically	significant	would	also	support	the	presence	of	a	low	grade	inflammatory	
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state.	Indeed,	as	discussed	above,	levels	of	CRP	have	been	shown	to	be	predictive	
of	mortality	in	haematological	malignancy.		
	
	
Conclusion	
	
In	conclusion,	the	global	aim	of	this	investigation	was	to	identify	a	circulating	
plasma	proteome	that	may	differentiate	systemic	mastocytosis	from	normal	
healthy	individuals.	The	results	reported	here	have	demonstrated	the	utility	of	
SWATH-MS	for	the	discovery	of	potential	biomarkers	of	systemic	mastocytosis.	The	
results	obtained	by	mass	spectrometry	have	demonstrated	significantly	increased	
levels	of	CRP,	CXCL7,	LBP,	TGFb1	and	PDGF	receptor-b	in	patients	with	systemic	
mastocytosis	when	compared	to	an	apparently	healthy	population.	Levels	of	b2M	
were	also	increased	in	patients	when	compared	to	controls,	however	the	
difference	did	not	reach	statistical	significance,	most	likely	due	to	the	large	spread	
of	results.	Results	obtained	by	ELISA	have	confirmed	the	results	obtained	by	mass-
spectrometry,	with	one	notable	exception,	that	B2M	was	significantly	increased	in	
patients	by	SWATH-MS,	but	not	when	quantified	by	ELISA.		
	
Limitations	
	
The	work	reported	here	has	a	number	of	limitations:	
• The	sample	numbers	were	small	(13	patients	and	7	controls),	although	the	
condition	is	relatively	rare	making	it	difficult	to	collect	large	numbers	of	
participants	from	a	single	clinical	site.		
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• The	demographic	data	for	some	of	the	patients	is	missing	and	the	c-KIT	
status	and	circulating	tryptase	levels	of	the	control	population	is	unknown,	
although	it	is	assumed	to	be	wild-type	and	normal	respectively.		
• The	age	of	the	patients	is	greater	than	the	age	of	the	controls	however,	this	
was	not	statistically	significant.	Likewise,	the	gender	distribution	between	
patients	and	controls	is	not	exactly	matched	with	a	female	predominance	in	
the	patient	population	
• The	results	reported	here	are	for	the	plasma	proteome	only	and	does	not	
include,	for	example	the	proteome	of	mononuclear	cell	and	bone	marrow	
fluid.		
	
Further	Work	
	
The	results	of	the	current	investigation	would	suggest	a	number	of	avenues	for	
further	work.	The	work	presented	here,	details	the	results	of	the	analysis	of	blood	
plasma	derived	from	a	peripheral	blood	sample	collected	at	the	antecubital	fossa.	
As	part	of	the	current	project,	the	author	also	isolated	peripheral	blood	and	bone	
marrow	derived	mononuclear	cells	together	with	bone	marrow	fluid,	however	time	
only	permitted	the	completion	of	peripheral	blood	plasma	sample.	The	next	stage,	
would	be	to	analyse	the	proteome	of	the	intra-cellular	lysate	of	mononuclear	cells,	
derived	from	peripheral	blood	and	bone	marrow,	in	addition	to	bone	marrow	fluid.		
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1.	Participant	information	sheet		
	
	
Version	1.1	4th	January	2017/18		
Title	of	Study:	Understanding	the	Molecular	Mechanisms	of	Mastocytosis		
	
Name	of	Researcher(s):	Dr	Ciaren	Graham,	Dr	Robert	Graham	and	Dr	Bethan	Myers		
We	would	like	to	invite	you	to	take	part	in	our	research	study.	Before	you	decide,	we	would	like	you	to	understand	
why	the	research	is	being	carried	out	and	what	it	would	involve	for	you.	Dr	Myers	will	go	through	this	information	
sheet	with	you	and	answer	any	questions	you	may	have	at	your	next	hospital	appointment.	We	expect	that	this	will	
take	about	15	minutes.	If	you	wish	to	ask	any	questions	about	the	study	before	your	appointment,	please	feel	free	to	
use	the	contact	details	on	page	4.	Please	take	time	to	read	the	following	information	carefully	and	discuss	it	with	
others	if	you	wish.	Ask	us	if	there	is	anything	that	is	not	clear	or	if	you	would	like	more	information.	Take	time	to	
decide	whether	or	not	you	wish	to	take	part.		
	
Part	1		
What	is	the	purpose	of	the	study?		
Mastocytosis	is	a	term	used	to	describe	a	blood	disorder	in	which	there	are	an	increased	number	of	mast	cells.	Mast	
cells	are	an	important	part	of	the	immune	system;	they	help	fight	infection	and	are	part	of	the	body’s	response	to	
allergens.	How	mastocytosis	develops	is	poorly	understood.	We	would	like	to	study	this	blood	disorder	from	bone	
marrow	and	blood	cells	in	patients	with	mastocytosis	using	a	technique	called	mass	spectrometry.	We	hope	that	by	
understanding	mastocytosis	development	this	will	lead	to	better	and	improved	therapies.		
Why	have	I	been	invited?		
You	have	been	invited	as	you	are	patient	affected	by	mastocytosis.	We	are	hoping	to	include	10	patients	currently	
affected	by	mastocytosis	in	this	study,	and	we	are	inviting	patients	who	currently	attend	the	mastocytosis	clinics	to	
consider	participating.		
Do	I	have	to	take	part?		
It	is	up	to	you	to	decide	whether	you	wish	to	take	part	in	the	study.	You	will	have	until	your	next	routine	clinic	
appointment,	or	as	long	as	you	need,	to	consider	the	information	in	this	sheet	and	decide	whether	or	not	to	take	
part.	A	member	of	the	research	team	will	go	through	all	the	information	with	you	again	on	the	day	of	your	
appointment	and	answer	any	questions	you	may	have.	If	you	agree	to	take	part,	we	will	then	ask	you	to	sign	a	
consent	form.	You	are	free	to	withdraw	at	any	time,	without	giving	a	reason.	This	would	not	affect	the	standard	of	
care	you	receive.	Version	1.1	4/01/2016	2		
	
What	will	happen	to	me	if	I	take	part?		
If	you	decide	to	take	part	in	the	study	the	only	difference	from	when	we	routinely	take	blood	and	bone	marrow	from	
you	is	that	three	extra	vials	(approximately	12mls)	of	blood	and	two	extra	vials	(approximately	8mls)	of	bone	marrow	
will	be	taken.	These	additional	samples	will	only	be	taken	when	you	are	having	blood	and/or	bone	marrow	samples	
taken	as	part	of	your	normal	care.	You	will	not	need	to	have	any	extra	procedures	as	part	of	the	study.		
What	are	the	possible	disadvantages	and	risks	of	taking	part?		
The	main	disadvantages	to	taking	part	are	the	possible	discomfort	associated	with	the	blood	test	and	the	bone	
marrow	aspiration,	both	of	which	you	will	have	as	part	of	your	care,	whether	you	chose	to	take	part	in	the	research	
study.	You	may	experience	a	slight	discomfort	when	blood	is	taken,	and	there	is	the	potential	for	a	small	bruise	to	
occur	afterwards.	You	may	also	find	the	bone	marrow	aspiration	uncomfortable	both	during	and	after	the	procedure.	
All	staff	performing	these	procedures	are	fully	trained	and	experienced	and	will	ensure	that	your	needs	are	met	
during	the	process.	Otherwise	there	are	no	known	risks	from	taking	part	in	this	study.	Taking	part	in	the	study	will	not	
affect	your	current	treatment.		
What	are	the	possible	benefits	of	taking	part?		
There	is	no	immediate	benefit	to	you	taking	part	in	this	study.	However,	the	information	we	get	from	this	study	may	
help	to	improve	the	treatment	of	yourself	and	others	affected	by	mastocytosis		
What	if	there	is	a	problem?		
Any	complaint	about	the	way	you	have	been	approached	or	treated	during	the	study	or	any	possible	harm	you	might	
suffer	will	be	addressed.	The	detailed	information	on	this	is	given	in	Part	2.		
Will	my	taking	part	in	the	study	be	kept	confidential?		
Yes.	We	will	follow	ethical	and	legal	practice	and	all	information	about	you	will	be	handled	in	confidence.	The	details	
are	included	in	Part	2.		
This	completes	part	1.		
If	the	information	in	Part	1	has	interested	you	and	you	are	considering	participation,	please	read	the	additional	
information	in	Part	2	before	making	any	decision.		
	
Part	2.		
What	will	happen	if	I	don’t	want	to	carry	on	with	the	study?	Version	1.1	4/01/2016	3		
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You	are	free	to	withdraw	from	the	study	at	any	time.	If	you	withdraw	from	the	study,	we	will	destroy	all	of	your	
identifiable	samples,	but	we	will	need	to	use	the	data	collected	up	to	your	withdrawal.		
What	if	there	is	a	problem?		
Complaints		
If	you	have	a	concern	about	any	aspect	of	this	study,	you	should	speak	to	Dr	Myers	who	will	do	her	best	to	answer	
your	questions.	If	you	remain	unhappy	and	wish	to	complain	formally,	you	can	do	this	by	contacting	[insert PALS 
details here] 	
Harm		
In	the	unlikely	event	that	something	does	go	wrong	and	you	are	harmed	during	your	participation	in	this	research	
study	there	are	no	special	compensation	arrangements.	However	if	you	are	harmed	and	this	is	due	to	someone‘s	
negligence	then	you	may	have	grounds	for	a	legal	action	for	compensation	against	United	Lincolnshire	Hospitals	NHS	
Trust,	but	you	may	have	to	pay	your	legal	costs.	The	normal	National	Health	Service	complaints	mechanisms	will	still	
be	available	to	you.		
Will	my	taking	part	in	this	study	be	kept	confidential?		
If	you	join	the	study,	some	parts	of	your	medical	records	and	the	data	collected	for	the	study	will	be	looked	at	by	
authorised	persons	from	the	organisations	sponsoring	and/or	organising	and	conducting	the	research	in	order	to	
check	that	the	study	is	being	carried	out	correctly.	All	will	have	a	duty	of	confidentiality	to	you	as	a	research	
participant	and	we	will	do	our	best	to	meet	this	duty.		
What	will	happen	to	any	samples	I	give?		
As	explained	to	you	in	Part	1	we	will	take	three	extra	vials	of	your	blood	and	bone	marrow	alongside	routine	samples	
taken	during	the	course	of	your	attendance	at	your	routine	clinical	appointments.	These	samples	will	be	transferred	
to	the	research	team	at	University	of	Lincoln	for	processing	and	then	to	the	University	of	Manchester	for	mass	
spectrometry	analysis.		
Only	the	authorised	researcher’s	team	will	have	access	to	your	samples	and	will	process	them	in	respect	of	rules	of	
confidentiality.		
The	remaining	samples	will	be	disposed	of	according	to	University	of	Lincoln	regulations	for	biological	samples.		
The	research	will	be	conducted	within	United	Lincolnshire	Hospitals	NHS	Trust,	the	University	of	Lincoln	and	the	
University	of	Manchester;	no	materials	will	be	sent	outside	of	the	UK.		
What	will	happen	to	the	results	of	the	research	study?	Version	1.1	4/01/2016	4		
	
The	results	of	this	study	may	be	presented	at	meetings,	conferences	and	submitted	for	publication	in	relevant	
medical	journals.	However,	no	personal	data	will	be	disclosed	within	the	results	and	all	samples	will	remain	
anonymous.		
A	webpage	has	been	created	for	this	study,	where	we	will	publish	the	studies	finding:	
http://lincolnproteomics.blogs.lincoln.ac.uk/mastocytosis-digital-proteomic-maps-2/	In	addition,	a	summary	of	the	
study	findings	will	also	be	published	on	the	ULHT	Lincolnshire	Clinical	Research	Facility	webpage	at	
www.ulh.nhs.uk/LCRF	following	completion	of	the	study.		
Who	is	organising	and	funding	the	research?		
The	research	is	being	co-sponsored	by	the	United	Lincolnshire	Hospitals	NHS	Trust	and	the	University	of	Lincoln	and	is	
funded	by	the	Mastocytosis	Charity.		
Who	has	reviewed	the	study?		
All	research	in	the	NHS	is	looked	at	by	an	independent	group	of	people,	called	a	Research	Ethics	Committee,	to	
protect	your	interests.	This	study	has	been	reviewed	and	given	favourable	opinion	by	the	NHS	Research	Ethics	
Committee.		
Further	Information	and	Contact	Details		
You	will	be	offered	a	copy	of	this	information	sheet	and	your	signed	consent	form	(if	applicable)	to	keep	for	future	
reference.		
	
If	you	would	like	any	further	information	
regarding	this	study	please	contact:		
	
Dr	Bethan	Myers		
	
	
	
	
Dr	Ciaren	Graham		
	
	
	
	
Dr	Robert	Graham		
United	Lincolnshire	Hospitals	NHS	Trust		 Manchester	Metropolitan	
University		
University	of	Manchester		
Greetwell	Road		 John	Dalton	Building		 Institute	of	Cancer	Sciences		
Lincoln		 Chester	Street		 27	Palatine	Road		
Lincolnshire		 Manchester		 Manchester		
LN2	5QY		 M1	5GD		 M20	3LJ		
01522	512512		 0161	2471146		 0161	2750005		
Bethan.Myers@ULH.nhs.uk		 c.graham@mmu.ac.uk		 Robert.graham@manchester.ac.uk		
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2.	Patient	Consent	Form		
	
	
 
 
Version 1.2 18/03/2016  1 
[Insert Trust header here]  
CONSENT FORM 
 
The Molecular Mechanisms of Mastocytosis 
Name of Researcher: Dr Bethan Myers – Consultant Haematologist, United Lincolnshire 
                                       Hospitals NHS Trust                                             
Dr Ciaren Graham – Senior lecturer, Manchester Metropolitan University 
              Dr Robert Graham – Senior Lecturer, University of Manchester 
 
Contact Details: 
Dr Bethan Myers: ULHT, Greetwell Road, Lincoln, Lincolnshire, LN2 5QY, (01522) 512 512 
Email: Bethan.Myers@ULH.nhs.uk 
Dr Ciaren Graham: Manchester Metropolitan University, John Dalton Building Chester Street 
Manchester M1 5GD, 0161 247 1146 E-mail c.graham@mmu.ac.uk 
University of Lincoln, Joseph Banks Laboratories, Email cgraham@lincoln.ac.uk 
Dr Robert Graham: University of Manchester, 27 Palatine Road, Manchester, M20 3LJ, 0161 
275 0005, robert.graham@manchester.ac.uk 
 
Please initial box each box 
 
1. I confirm that I have read and understand the information  
sheet dated...... (version............) for the above study.  
I have had the opportunity to consider the information, ask  
questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I  
am free to withdraw at any time without giving any reason,  
without my medical care or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes  
and data collected during the study, may be looked at by  
individuals from the regulatory authorities, the NHS Trust,  
or the Sponsor where it is relevant to my taking part in this research. I give  
permission for these individuals to have access to my records.  
 
 
4. I agree to take part in the above study.  
 
Name of Patient     Signature    Date 
 
-----------------------------------------   -----------------------------------  ------------- 
Name of Person taking consent   Signature    Date 
 
----------------------------------------   -----------------------------------  ------------- 
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3.	Heathy	Control	Participant	Consent	Form		
01/01/18	
Amy	McMullen	
Department	of	Healthcare	Science	
John	Dalton		
Manchester	Metropolitan	University	
Tel:	0161-	247-2000	
	
	
Consent	Form 
	
 
Title of Project: 	
	Understanding	the	Molecular	Mechanisms	of	Mastocytosis	  
 
Name of Researcher: Amy McMullen  
Name of Supervisor: Dr C Graham  
 
Participant Identification Code for this project: 
                  
1. I confirm that I have read and understood the information sheet  
dated …. for the above project and have had the  
opportunity to ask questions about the interview procedure. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason to the named researcher. 
 
3. I understand that my blood samples will be used for analysis for this 
research project.  
 
4. I give/do not give permission for any blood samples to be archived as part 
of this research project, making it available to future researchers. 
 
5. I agree to take part in the above research project. 
 
 
 
________________________ ________________         
____________________ 
Name of Participant Date
 Signature 
 
_________________________ ________________         
____________________ 
Researcher Date
 Signature 
To be signed and dated in presence of the participant 
 
Once this has been signed, you will receive a copy of your signed and dated 
consent form and information sheet by post. 
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4.	NRES	Letter		
	
	
	
	
	
	
	
 
London - City & East Research Ethics Committee 
Bristol Research Ethics Committee Centre 
Whitefriars 
Level 3, Block B 
Lewins Mead 
Bristol 
BS1 2NT 
 
Telephone: 02071048033/53 
10 May 2016 
 
Dr Ciaren Graham 
Senior Lecture 
Manchester Metropolitan University 
John Dalton Building  
Chester Street 
Manchester  
M1 5GD 
 
 
Dear Dr Graham 
 
Study title: Defining the Molecular Mechanisms of Mastocytosis 
using Mass Spectrometry 
REC reference: 16/LO/0787 
IRAS project ID: 192830 
 
Thank you for your response of 04 May 2016, responding to the Proportionate Review  
Sub-Committee’s request for changes to the documentation for the above study. 
 
The revised documentation has been reviewed and approved by the sub-committee. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter.  The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 
contact point, wish to make a request to defer, or require further information, please contact 
the REC Manager Mr Rajat Khullar, nrescommittee.london-cityandeast@nhs.net. Under very 
limited circumstances (e.g. for student research which has received an unfavourable opinion), 
it may be possible to grant an exemption to the publication of the study. 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
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5.	List	of	Identified	proteins		
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6.	List	of	Significantly	Up	Regulated	proteins		
	
PROTEIN	 p-value	
Fold	
Change	
1-phosphatidylinositol	4,5-bisphosphate	phosphodiesterase	gamma-1		 0.00	 1.58	
10	kDa	heat	shock	protein,	mitochondrial		 0.03	 1.61	
14-3-3	protein	beta/alpha		 0.00	 1.68	
14-3-3	protein	zeta/delta		 0.00	 1.87	
26S	protease	regulatory	subunit	6A		 0.00	 1.76	
26S	proteasome	non-ATPase	regulatory	subunit	1		 0.00	 1.58	
26S	proteasome	non-ATPase	regulatory	subunit	5		 0.00	 1.67	
3-hydroxyacyl-CoA	dehydrogenase	type-2		 0.01	 1.58	
4-hydroxyphenylpyruvate	dioxygenase		 0.01	 1.63	
40S	ribosomal	protein	S12		 0.00	 2.49	
40S	ribosomal	protein	S13	 0.01	 1.67	
40S	ribosomal	protein	S2		 0.02	 1.50	
40S	ribosomal	protein	S24	 0.00	 1.72	
40S	ribosomal	protein	S4,	X	isoform		 0.00	 1.87	
40S	ribosomal	protein	SA		 0.00	 1.86	
4F2	cell-surface	antigen	heavy	chain	 0.02	 1.55	
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	4		 0.01	 1.60	
6-phosphogluconate	dehydrogenase,	decarboxylating		 0.00	 1.51	
60S	acidic	ribosomal	protein	P0		 0.04	 1.60	
60S	ribosomal	protein	L13		 0.02	 2.36	
60S	ribosomal	protein	L19		 0.05	 1.65	
60S	ribosomal	protein	L30		 0.01	 1.67	
60S	ribosomal	protein	L7		 0.03	 1.58	
Acetyl-CoA	acetyltransferase,	cytosolic		 0.04	 1.57	
Actin-related	protein	2		 0.01	 1.68	
Actin-related	protein	2/3	complex	subunit	5		 0.00	 1.71	
Activated	CDC42	kinase	1		 0.00	 1.60	
Acyl-coenzyme	A	thioesterase	2,	mitochondrial		 0.03	 1.94	
Acyl-protein	thioesterase	1		 0.00	 1.65	
Acylamino-acid-releasing	enzyme		 0.00	 1.73	
Adenosine	deaminase		 0.01	 1.58	
Adenylate	kinase	isoenzyme	1		 0.00	 1.84	
Adipocyte	enhancer-binding	protein	1		 0.00	 2.39	
Adipocyte	plasma	membrane-associated	protein		 0.00	 1.51	
Alanine	aminotransferase	1		 0.00	 2.04	
Alcohol	dehydrogenase	[NADP(+)]		 0.01	 1.62	
Aldehyde	dehydrogenase,	mitochondrial		 0.03	 1.66	
Alpha-1-acid	glycoprotein	1		 0.00	 1.73	
Alpha-enolase		 0.00	 1.83	
Alpha-mannosidase	2		 0.00	 2.91	
Aminoacylase-1		 0.05	 1.82	
Amyloid	beta	A4	protein		 0.01	 1.83	
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Angiogenin		 0.05	 1.67	
Angiopoietin-related	protein	3		 0.01	 1.82	
Annexin	A2		 0.00	 1.51	
Annexin	A3		 0.01	 1.70	
AP-1	complex	subunit	beta-1		 0.01	 1.56	
ATP	synthase	subunit	O,	mitochondrial		 0.03	 2.99	
ATP-dependent	RNA	helicase	DDX3Y	 0.00	 2.02	
Bcl-2-like	protein	13		 0.00	 2.10	
Beta-1,4-glucuronyltransferase	1		 0.03	 5.34	
Beta-2-microglobulin		 0.00	 1.90	
Beta-actin-like	protein	2		 0.01	 1.78	
Beta-glucuronidase		 0.03	 1.84	
Beta-mannosidase		 0.01	 1.71	
Bisphosphoglycerate	mutase		 0.00	 1.94	
Bone	marrow	proteoglycan		 0.00	 1.54	
C-C	motif	chemokine	15	 0.02	 1.72	
C-reactive	protein		 0.00	 3.62	
Cadherin-6		 0.00	 1.86	
Cadherin-related	family	member	5		 0.01	 1.55	
Calcium/calmodulin-dependent	protein	kinase	type	II	subunit	beta		 0.00	 1.98	
Carbonic	anhydrase	3		 0.05	 1.84	
Carbonyl	reductase	[NADPH]	1		 0.00	 2.07	
Cartilage	oligomeric	matrix	protein		 0.00	 1.97	
Cathepsin	F		 0.00	 2.41	
CD5	antigen-like		 0.02	 2.17	
CDK5	regulatory	subunit-associated	protein	3		 0.05	 1.81	
Cell	growth	regulator	with	EF	hand	domain	protein	1		 0.00	 3.38	
Centromere	protein	F		 0.00	 1.55	
Chloride	intracellular	channel	protein	4		 0.00	 1.68	
Cofilin-1		 0.00	 1.75	
Coiled-coil	domain-containing	protein	25		 0.03	 1.83	
Collagen	alpha-1(XVIII)	chain		 0.01	 1.50	
Complement	C1q	subcomponent	subunit	A	 0.00	 1.85	
Complement	C1q	subcomponent	subunit	C		 0.00	 1.57	
Complement	C4-B		 0.00	 1.61	
Complement	factor	H-related	protein	5		 0.00	 1.67	
Copine-1		 0.01	 1.68	
Cullin-associated	NEDD8-dissociated	protein	1		 0.00	 1.64	
Cysteine	and	histidine-rich	domain-containing	protein	1		 0.00	 1.82	
Cysteine-rich	protein	1		 0.03	 5.16	
Cytosolic	5'-nucleotidase	3A		 0.02	 1.57	
Cytosolic	non-specific	dipeptidase	 0.00	 1.86	
D-3-phosphoglycerate	dehydrogenase		 0.00	 1.60	
Deleted	in	malignant	brain	tumors	1	protein		 0.04	 1.64	
Desmocollin-1		 0.05	 1.55	
Di-N-acetylchitobiase		 0.01	 1.67	
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Dihydropyrimidinase-related	protein	2		 0.00	 1.75	
Dimethylglycine	dehydrogenase,	mitochondrial		 0.02	 1.57	
Dynamin-2		 0.00	 1.56	
E3	ubiquitin/ISG15	ligase	TRIM25		 0.00	 1.55	
Ectonucleoside	triphosphate	diphosphohydrolase	5		 0.01	 1.64	
EGF-containing	fibulin-like	extracellular	matrix	protein	1		 0.00	 1.62	
EH	domain-containing	protein	1		 0.00	 1.80	
Elongation	factor	1-gamma		 0.02	 1.68	
Endoglin		 0.04	 1.51	
Endoplasmic	reticulum	aminopeptidase	2		 0.01	 1.68	
Enoyl-CoA	hydratase,	mitochondrial		 0.01	 1.50	
Epsin-1		 0.00	 1.82	
Ester	hydrolase	C11orf54		 0.01	 1.78	
Eukaryotic	initiation	factor	4A-I		 0.00	 2.11	
Eukaryotic	initiation	factor	4A-II		 0.04	 1.50	
Eukaryotic	translation	initiation	factor	3	subunit	I	 0.00	 1.50	
Eukaryotic	translation	initiation	factor	3	subunit	J		 0.01	 1.55	
Eukaryotic	translation	initiation	factor	4E		 0.03	 3.46	
Eukaryotic	translation	initiation	factor	5A-1	 0.01	 1.72	
Exosome	complex	component	RRP41		 0.01	 2.31	
Exportin-1		 0.00	 1.58	
Extracellular	glycoprotein	lacritin	 0.05	 1.80	
Ezrin		 0.00	 1.64	
Farnesyl	pyrophosphate	synthase		 0.00	 1.56	
Fatty	acid-binding	protein,	liver		 0.05	 1.50	
Ferritin	heavy	chain		 0.05	 2.98	
Ferritin	light	chain		 0.00	 1.69	
Fibulin-2		 0.00	 1.53	
Filamin-B		 0.00	 1.54	
Focal	adhesion	kinase	1		 0.00	 2.16	
Follistatin-related	protein	1		 0.01	 1.83	
Gamma-aminobutyric	acid	receptor-associated	protein-like	2		 0.04	 1.62	
GDH/6PGL	endoplasmic	bifunctional	protein		 0.01	 1.80	
General	transcription	factor	IIF	subunit	1		 0.01	 1.70	
Glial	fibrillary	acidic	protein		 0.01	 2.07	
Glutamate	dehydrogenase	1,	mitochondrial		 0.00	 1.87	
Glutamyl	aminopeptidase		 0.00	 1.83	
Glutathione	peroxidase	1	 0.00	 2.17	
Glutathione	synthetase		 0.00	 1.81	
Glycerol-3-phosphate	dehydrogenase	[NAD(+)],	cytoplasmic		 0.00	 1.68	
Glycogen	debranching	enzyme		 0.00	 1.65	
Glycogen	phosphorylase,	brain	form		 0.00	 1.73	
Glycogen	phosphorylase,	liver	form		 0.00	 1.53	
GMP	reductase	1		 0.00	 2.18	
GTP:AMP	phosphotransferase	AK3,	mitochondrial		 0.00	 1.64	
Guanine	nucleotide-binding	protein	subunit	alpha-13		 0.00	 1.53	
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Heat	shock	70	kDa	protein	1A	 0.00	 1.70	
Hematological	and	neurological	expressed	1	protein		 0.05	 1.58	
Hemoglobin	subunit	alpha		 0.01	 1.82	
Hemoglobin	subunit	beta		 0.02	 1.88	
Hemoglobin	subunit	delta		 0.00	 1.78	
Heterogeneous	nuclear	ribonucleoprotein	K		 0.04	 1.64	
Heterogeneous	nuclear	ribonucleoprotein	M		 0.00	 1.50	
High	mobility	group	protein	B2		 0.00	 1.64	
High	mobility	group	protein	B3		 0.01	 1.68	
Histidine	protein	methyltransferase	1	homolog	 0.00	 2.44	
Histone	H3.3		 0.05	 2.83	
HLA	class	I	histocompatibility	antigen,	B44	alfa	chain	 0.02	 1.79	
HLA	class	II	histocompatibility	antigen,	DR	alpha	chain		 0.01	 1.95	
Host	cell	factor	1		 0.01	 1.61	
Hydroxyacylglutathione	hydrolase,	mitochondrial		 0.00	 1.59	
Hydroxysteroid	dehydrogenase-like	protein	2		 0.01	 1.83	
Hypoxanthine-guanine	phosphoribosyltransferase		 0.03	 1.74	
Ig	alpha-1	chain	C	region		 0.00	 3.06	
Ig	alpha-2	chain	C	region		 0.00	 3.01	
Ig	gamma-2	chain	C	region		 0.01	 3.36	
Ig	gamma-4	chain	C	region		 0.01	 4.56	
Ig	heavy	chain	constant	 0.03	 6.39	
Ig	heavy	constant	gamma	1	 0.00	 2.80	
Ig	heavy	constant	gamma	3	 0.05	 2.77	
Ig	Heavy	Variable	3-33	 0.00	 4.06	
Ig	heavy	variable	3-7	 0.00	 2.11	
Ig	HV4-34	 0.04	 2.99	
Ig	kappa	chain	C	region		 0.00	 4.47	
Ig	kappa	variable	3-20	 0.02	 2.15	
Ig	mu	chain	C	region		 0.04	 4.10	
Immunoglobulin	heavy	variable	1-46		 0.02	 2.14	
Immunoglobulin	heavy	variable	3-48		 0.00	 2.18	
Immunoglobulin	J	chain		 0.05	 2.95	
Immunoglobulin	kappa	variable	1-16		 0.00	 2.02	
Immunoglobulin	kappa	variable	2-30		 0.02	 1.93	
Immunoglobulin	lambda	variable	3-19		 0.00	 2.74	
Immunoglobulin	lambda	variable	3-21		 0.00	 3.76	
Immunoglobulin	lambda	variable	3-25	 0.01	 1.62	
Importin-11		 0.00	 1.88	
Importin-7		 0.01	 1.57	
Insulin-like	growth	factor-binding	protein	6		 0.02	 1.62	
Intron-binding	protein	aquarius		 0.00	 1.60	
Isochorismatase	domain-containing	protein	2		 0.00	 1.91	
Junction	plakoglobin		 0.03	 1.61	
Keratin,	type	I	cuticular	Ha3-II		 0.02	 1.61	
Keratin,	type	I	cytoskeletal	15		 0.01	 1.66	
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Keratin,	type	I	cytoskeletal	16		 0.00	 2.08	
Keratin,	type	II	cuticular	Hb5		 0.01	 1.96	
Keratin,	type	II	cytoskeletal	3	 0.01	 1.94	
KRR1	small	subunit	processome	component	homolog		 0.03	 1.73	
L-lactate	dehydrogenase	A	chain		 0.02	 1.55	
Laminin	subunit	beta-1		 0.00	 1.62	
Latent-transforming	growth	factor	beta-binding	protein	4		 0.01	 2.09	
Leucine	zipper	protein	1		 0.00	 1.72	
Leucine-rich	alpha-2-glycoprotein		 0.00	 1.73	
Leucine-rich	repeat	flightless-interacting	protein	1		 0.00	 1.54	
LIM	and	senescent	cell	antigen-like-containing	domain	protein	1		 0.04	 1.68	
Lipopolysaccharide-binding	protein		 0.00	 2.03	
LisH	domain	and	HEAT	repeat-containing	protein	KIAA1468		 0.03	 1.99	
Low-density	lipoprotein	receptor		 0.00	 1.80	
Lysosomal	Pro-X	carboxypeptidase		 0.00	 1.95	
Lysosomal	protective	protein		 0.00	 1.77	
Macrophage	colony-stimulating	factor	1	receptor		 0.00	 1.73	
Maltase-glucoamylase,	intestinal		 0.05	 1.50	
Mannose-binding	protein	C		 0.02	 1.50	
Matrin-3		 0.00	 1.65	
Matrix	Gla	protein		 0.04	 2.15	
Matrix	metalloproteinase-9		 0.00	 1.95	
Mediator	of	RNA	polymerase	II	transcription	subunit	13-like		 0.03	 1.65	
Melanotransferrin		 0.00	 2.73	
Mesothelin		 0.03	 1.55	
Metalloproteinase	inhibitor	1		 0.00	 1.78	
Microtubule-associated	protein	1B		 0.00	 1.80	
Minor	histocompatibility	protein	HA-1		 0.00	 1.67	
Mitochondrial	import	inner	membrane	translocase	subunit	Tim13		 0.05	 1.71	
Mitogen-activated	protein	kinase	14		 0.01	 1.75	
Myelin	basic	protein		 0.00	 1.98	
N-acetylglucosamine-1-phosphotransferase	subunit	gamma		 0.02	 2.13	
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase		 0.00	 1.74	
Na(+)/H(+)	exchange	regulatory	cofactor	NHE-RF1		 0.00	 2.09	
NADP-dependent	malic	enzyme		 0.00	 1.93	
Neprilysin		 0.01	 1.68	
Neurogenic	locus	notch	homolog	protein	2		 0.00	 1.54	
Neutrophil	cytosol	factor	4		 0.01	 1.79	
Neutrophil	elastase		 0.00	 1.80	
Nicotinate	phosphoribosyltransferase		 0.00	 1.51	
Nicotinate-nucleotide	pyrophosphorylase	[carboxylating]		 0.00	 2.15	
NIF3-like	protein	1		 0.04	 1.82	
Nuclear	autoantigenic	sperm	protein		 0.00	 1.57	
Nuclear	pore	complex	protein	Nup50		 0.01	 1.84	
Nucleoside	diphosphate	kinase	B		 0.01	 2.62	
obsolete	 0.01	 2.37	
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Pancreatic	alpha-amylase		 0.00	 2.87	
Pancreatic	secretory	granule	membrane	major	glycoprotein	GP2		 0.00	 4.31	
Pantetheinase		 0.03	 1.97	
PDZ	and	LIM	domain	protein	5		 0.00	 1.68	
Pentatricopeptide	repeat	domain-containing	protein	3,	mitochondrial		 0.02	 1.58	
Peptidoglycan	recognition	protein	1		 0.01	 2.00	
Peptidyl-glycine	alpha-amidating	monooxygenase		 0.00	 1.62	
Peptidyl-prolyl	cis-trans	isomerase	A		 0.00	 1.59	
Peptidyl-prolyl	cis-trans	isomerase	FKBP4		 0.00	 2.16	
Peptidyl-prolyl	cis-trans	isomerase	FKBP5		 0.00	 1.64	
Peroxidasin	homolog		 0.03	 1.67	
Peroxiredoxin-2		 0.00	 1.84	
Peroxiredoxin-6		 0.00	 2.10	
Phosphatidylinositol	4-phosp	3-kinase	C2	domain-containing	
subunit	beta		 0.01	 1.92	
Phosphatidylinositol	5-phosphate	4-kinase	type-2	alpha		 0.01	 1.65	
Phosphofurin	acidic	cluster	sorting	protein	1		 0.00	 1.67	
Phosphoglycerate	mutase	1		 0.02	 1.64	
Phospholipid	transfer	protein		 0.00	 1.61	
Plastin-1		 0.03	 1.68	
Platelet	basic	protein	 0.00	 4.83	
Platelet	factor	4		 0.02	 1.83	
Platelet-derived	growth	factor	receptor	beta		 0.05	 2.02	
Pleckstrin		 0.00	 1.90	
Poly(rC)-binding	protein	1		 0.02	 1.79	
Polyadenylate-binding	protein	1		 0.02	 1.61	
Polymeric	immunoglobulin	receptor		 0.02	 2.47	
POTE	ankyrin	domain	family	member	F	 0.00	 1.83	
POTE	ankyrin	domain	family	member	J		 0.00	 2.15	
Prefoldin	subunit	6		 0.02	 1.75	
Probable	ATP-dependent	RNA	helicase	DDX17		 0.00	 1.63	
Probable	ATP-dependent	RNA	helicase	DDX5		 0.00	 1.87	
Probable	phospholipid-transporting	ATPase	IF		 0.01	 2.02	
Profilin-1		 0.00	 1.63	
Prolyl	endopeptidase	FAP		 0.01	 2.53	
Prostaglandin	reductase	1		 0.01	 1.54	
Prostaglandin-H2	D-isomerase		 0.00	 1.66	
Proteasome	activator	complex	subunit	2		 0.02	 1.53	
Proteasome	subunit	alpha	type-2		 0.04	 1.64	
Proteasome	subunit	alpha	type-3		 0.00	 1.70	
Proteasome	subunit	alpha	type-5		 0.00	 1.57	
Proteasome	subunit	beta	type-6	 0.02	 1.79	
Proteasome	subunit	beta	type-7		 0.01	 1.64	
Protein	4.1		 0.05	 1.62	
Protein	disulfide-isomerase		 0.00	 1.66	
Protein	disulfide-isomerase	A6		 0.00	 1.55	
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Protein	FAM3C		 0.00	 1.69	
Protein	FAM76B		 0.01	 2.25	
Protein	flightless-1	homolog		 0.00	 1.59	
Protein	MON2	homolog		 0.05	 1.69	
Protein	PBDC1		 0.02	 1.82	
Protein	phosphatase	1	regulatory	subunit	14B		 0.02	 1.52	
Protein	POF1B		 0.00	 1.99	
Protein	S100-A10		 0.01	 1.60	
Protein	S100-A11		 0.04	 1.51	
Protein	S100-A6		 0.03	 1.97	
Protein	S100-A7		 0.00	 1.97	
Protein	S100-A8		 0.01	 1.91	
Protein	S100-A9		 0.00	 1.94	
Protein-L-isoaspartate(D-aspartate)	O-methyltransferase		 0.00	 1.75	
Prothymosin	alpha		 0.05	 13.69	
Pterin-4-alpha-carbinolamine	dehydratase		 0.04	 1.89	
Purine	nucleoside	phosphorylase		 0.00	 2.56	
Putative	ATP-dependent	RNA	helicase	DDX11-like	protein	8		 0.03	 2.31	
Pyruvate	kinase	PKM		 0.00	 1.69	
Radixin		 0.02	 1.51	
Ragulator	complex	protein	LAMTOR3		 0.01	 3.95	
Ras	GTPase-activating-like	protein	IQGAP2		 0.04	 1.54	
RAS	guanyl-releasing	protein	2		 0.02	 2.21	
Ras	suppressor	protein	1		 0.00	 1.60	
Ras-related	protein	Rab-7a		 0.00	 1.79	
Receptor-type	tyrosine-protein	phosphatase	eta		 0.01	 1.74	
Reticulon-4		 0.02	 2.20	
Retinal	dehydrogenase	1		 0.00	 1.52	
Retinol-binding	protein	1		 0.03	 1.59	
Rho-associated	protein	kinase	2		 0.01	 1.54	
RNA-binding	protein	3		 0.02	 1.65	
RNMT-activating	mini	protein		 0.03	 3.99	
rRNA	2'-O-methyltransferase	fibrillarin		 0.00	 1.88	
Secretogranin-1		 0.01	 1.88	
Septin-6		 0.01	 1.72	
Septin-7		 0.01	 1.61	
Serine/arginine	repetitive	matrix	protein	2		 0.01	 1.60	
Serine/threonine-protein	kinase	10		 0.00	 1.83	
Serine/threonine-protein	phosp	2A	65	kDa	regulatory	subunit	A	alpha	
isoform		 0.00	 1.91	
Serine/threonine-protein	phosp	6	catalytic	subunit		 0.02	 1.52	
Serine/threonine-protein	phosp	PP1-gamma	catalytic	subunit		 0.01	 2.24	
Serpin	B3		 0.03	 1.63	
Serpin	B5		 0.01	 1.70	
Serum	amyloid	A-1	protein		 0.00	 1.73	
Serum	amyloid	A-2	protein		 0.01	 1.85	
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Sex	hormone-binding	globulin		 0.01	 1.62	
Small	subunit	processome	component	20	homolog		 0.00	 1.97	
Sorbitol	dehydrogenase		 0.00	 1.89	
Spectrin	beta	chain,	non-erythrocytic	1		 0.00	 1.54	
Sphingomyelin	phosphodiesterase	4		 0.00	 2.28	
Staphylococcal	nuclease	domain-containing	protein	1		 0.02	 1.51	
TAR	DNA-binding	protein	43		 0.01	 1.60	
Thioredoxin		 0.01	 1.70	
Thioredoxin	domain-containing	protein	5		 0.00	 1.91	
THO	complex	subunit	4		 0.03	 1.79	
Thrombospondin-1		 0.00	 3.01	
Thrombospondin-2		 0.02	 2.20	
Thy-1	membrane	glycoprotein		 0.02	 1.77	
Thymosin	beta-4		 0.00	 2.28	
Transcobalamin-1		 0.00	 1.88	
Transcription	factor	BTF3		 0.00	 1.67	
Transcription	intermediary	factor	1-beta		 0.00	 1.61	
Transferrin	receptor	protein	1		 0.00	 2.13	
Transforming	growth	factor	beta-1		 0.00	 2.06	
Transgelin-2		 0.00	 1.67	
Transmembrane	glycoprotein	NMB		 0.00	 1.52	
Triosephosphate	isomerase		 0.00	 1.53	
Tripeptidyl-peptidase	1		 0.04	 2.32	
Tripeptidyl-peptidase	2		 0.00	 1.53	
Tropomodulin-3		 0.02	 1.73	
Trypsin-2		 0.02	 1.59	
Tryptophan--tRNA	ligase,	cytoplasmic		 0.00	 1.86	
Tubulin	alpha-1C	chain		 0.01	 1.93	
Tubulin	beta	chain		 0.00	 1.60	
Tubulin-specific	chaperone	A		 0.04	 1.55	
Ubiquitin	carboxyl-terminal	hydrolase	isozyme	L5		 0.03	 1.67	
Ubiquitin-conjugating	enzyme	E2	N		 0.05	 1.63	
Ubiquitin-conjugating	enzyme	E2	variant	2		 0.00	 2.20	
Unhealthy	ribosome	biogenesis	protein	2	homolog		 0.00	 1.82	
UPF0587	protein	C1orf123		 0.00	 3.14	
V-type	proton	ATPase	catalytic	subunit	A		 0.01	 1.69	
Vacuolar	protein	sorting-associated	protein	29		 0.00	 1.79	
Vascular	cell	adhesion	protein	1		 0.00	 1.76	
Vascular	endothelial	growth	factor	receptor	1		 0.04	 1.72	
Versican	core	protein		 0.01	 2.67	
Voltage-dependent	anion-selective	channel	protein	1	 0.00	 2.44	
X-ray	repair	cross-complementing	protein	6		 0.00	 1.55	
Zinc	finger	CCCH	domain-containing	protein	4		 0.05	 1.63	
Zinc	finger	protein	318		 0.01	 2.21	
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7.	List	of	Significantly	Down	Regulated	proteins	
	
Group	 p-value	
Fold	
Change	
Actin-related	protein	2/3	complex	subunit	2		 0.01	 0.21	
Apolipoprotein	A-II		 0.00	 0.56	
Beta-Ala-His	dipeptidase		 0.00	 0.58	
Ficolin-2	 0.01	 0.53	
Keratin,	type	II	cytoskeletal	1		 0.00	 0.56	
Keratin,	type	II	cytoskeletal	1b		 0.00	 0.58	
Serpin	H1		 0.01	 0.65	
Serum	amyloid	A-4	protein		 0.05	 0.59	
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Abstract Content: Mastocytosis is a myeloproliferative disease that is characterised by the accumulation of neoplastic mast cells in
one or several organs resulting in mediator release symptoms, tissue damage and, in aggressive cases, organ failure. The vast majority
of adult patients with mastocytosis present with systemic mastocytosis (SM) and it is defined as mast cell accumulation in one or
more visceral organs. Despite advances in the understanding of myeloid neoplasia the aetiology of mastocytosis is poorly understood.
Around 80-90% of patients with SM harbour a somatic activating mutation in the c-KIT gene (D816V). The D816V mutation results
in the constitutive activation of the c-Kit receptor causing the activation of multiple signalling pathways resulting in an increased
proliferative and survival advantage of the mast cell lineage. However, the presence of the c-KIT mutation does not explain the
heterogeneous clinical behaviour of the disease, and the molecular mechanisms underlying the different subtypes of SM remain
largely elusive.There is a clear need to develop strategies that will aid in the understanding of the molecular pathology of SM.  We
carried-out a global discovery proteome analysis of the plasma of SM patients (n=3) and compared these to healthy control plasma
samples(n=3); using the new high resolution mass spectrometry protocol Sequential Window Acquisition of all Theoretical fragment-
ion spectra mass spectrometry (SWATH MS). SM patients were chosen for eligibility using the WHO selection criteria. Samples
were immunodepleted and SWATH MS permanent digital proteomic maps were generated for all samples on an 6600 TripleTOF
mass spectrometer (AB Sciex, Warrington, UK) and an Eksigent 1D+ Nano LC systems (Eksigent, Dublin, CA) all samples were run
with triplicate mass spectrometry injections per sample. We identified ~1000 proteins in each of the samples at a 5% FDR and they
were mapped on to their relevant pathways using KEGG. Heatmaps and volcano plots were generated using the MSstats program in
the R environment. Bioinformatic analysis and pathway mapping demonstrated that a number of immunological and metabolic
pathways were significantly upregulated in the plasma of the mastocytosis patients including B cell proliferation, phagocytosis
response and calcium signalling. Full characterisation of key regulatory pathways in relation to mastocytosis disease aetiology will
identify new direct cellular targets potentially paving the way for new bespoke treatment strategies in this blood disorder.
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